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The impact of the peripherally selective α2-adrenoceptor antagonist, vatinoxan, on selected 
pharmacodynamic and pharmacokinetic properties of two selective α2-adrenoceptor agonists, 
medetomidine and dexmedetomidine, were investigated in sheep. Moreover, certain interactions 
between vatinoxan and atipamezole, a specific α2-adrenoceptor antagonist, were evaluated.  
The initial objective of this study was to identify a dose of vatinoxan that would best mitigate the 
undesirable cardiopulmonary changes produced by intramuscular (IM) medetomidine-ketamine in 
sheep. Specifically, three doses of vatinoxan (150, 300 and 600 μg/kg) or saline were combined in 
the same syringe with medetomidine (30 μg/kg) and ketamine (1 mg/kg) and given IM. Systemic 
hemodynamics, arterial blood gas tensions, clinical sedation and plasma drug concentrations were 
compared, both before and after reversal with IM atipamezole (150 μg/kg). The middle dose of 
vatinoxan (300 μg/kg), which appeared to be optimal among the other doses, was then added to 
medetomidine (30 μg/kg) and co-administered IM, followed by atipamezole for reversal. Last, the 
influence of intravenous pre-treatment with vatinoxan on dexmedetomidine-induced 
cardiopulmonary alterations was investigated in sevoflurane-anesthetized sheep. 
Following concomitant IM administration, vatinoxan dose-dependently attenuated some of 
medetomidine’s cardiopulmonary side effects. Vatinoxan did not significantly affect the level of 
sedation or the plasma concentrations of drugs when ketamine was included in the same syringe. 
Conversely, vatinoxan significantly increased the plasma concentrations of medetomidine, and 
accelerated the onset and intensified the degree of sedation when compared with the agonist alone. 
Moreover, recoveries after atipamezole-reversal were more complete in the presence of vatinoxan. 
No deleterious effects were noted between vatinoxan and atipamezole. Pre-treatment with vatinoxan 
prevented all dexmedetomidine-induced pulmonary alterations in sheep anesthetized with 
sevoflurane. 
In conclusion, vatinoxan alleviated or prevented the unwanted cardiopulmonary effects of (dex-) 
medetomidine by blocking the peripheral α2-adrenoceptors. Presumably, when co-administered IM 
in the same syringe, vatinoxan accelerated the absorption of medetomidine and increased its 
concentration in blood, which resulted in a faster and more intense sedation than when the agonist 
was used alone. Vatinoxan also decreased later exposure to dexmedetomidine, which appeared to 
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Alpha2-adrenoceptor agonists are extensively used in veterinary clinical practice for their sedative, 
anxiolytic, antinociceptive and anesthetic-sparing properties. In ruminants, particularly sheep, their 
use is associated with cardiopulmonary adverse effects, most notably: arterial hypoxemia, 
vasoconstriction, and decreases in heart rate, cardiac output and oxygen delivery (Aziz & Carlyle, 
1978; Bryant et al., 1996; Celly et al., 1997a; Kästner et al., 2005; Raekallio et al., 2010). The extent 
of these effects depends mainly on the dose of the agonist and its route of administration. Racemic 
medetomidine and its active enantiomer, dexmedetomidine, are the most potent and selective α2-
adrenoceptor agonists currently available for veterinary use. In ruminants, medetomidine is widely 
used either alone or in combination with e.g. ketamine to produce reliable sedation or anesthesia for 
diagnostic and surgical procedures. The desired sedative effects of α2-adrenoceptor agonists are 
mediated via α2-adrenoceptors within the central nervous system (CNS) (Doze et al., 1989; Maze & 
Fujinaga, 2000), whereas α2-adrenoceptors located in the vasculature mediate the initial 
hemodynamic consequences (Docherty & McGrath, 1980; Kamibayashi & Maze, 2000).  
Vatinoxan, previously known as L-659,066 and MK-467, is a peripherally selective α2-adrenoceptor 
antagonist that penetrates poorly into the mammalian CNS (Clineschmidt et al., 1988). Over the past 
decade, various combinations of vatinoxan and α2-adrenoceptor agonists have been evaluated in 
several animal species (Bryant et al., 1998; Enouri et al., 2008; Honkavaara et al., 2008; 2011; 2017a, 
b; Rolfe et al., 2012; Vainionpää et al., 2013; Kaartinen et al., 2014 Salla et al., 2014b; de Vries et 
al., 2016). The outcomes from these studies are promising as vatinoxan has repeatedly attenuated the 
peripherally-mediated hemodynamic effects with no clinically relevant effect on the sedative efficacy 
of the used agonists (Honkavaara et al., 2008; Restitutti et al., 2011; Tapio et al., 2018). The 
cardiovascular effects of vatinoxan have previously been studied after IV co-administration with 
dexmedetomidine in sheep (Raekallio et al., 2010). Therefore, the primary aim of this thesis was to 
further elucidate this interaction in sheep following concurrent IM administration with and without 
ketamine, focusing primarily on the cardiopulmonary function and sedation. It was hypothesized that 
medetomidine-induced adverse cardiopulmonary effects would be attenuated by vatinoxan while the 
sedation would not be negatively impacted. Additionally, the effects of pre-treatment with vatinoxan 
on dexmedetomidine-induced cardiopulmonary alteration were investigated in sevoflurane-
anesthetized sheep. It was postulated that pre-administration of vatinoxan would prevent the increase 
in airway resistance and pulmonary edema formation, thus attenuating the decrease in arterial partial 
pressure of oxygen following dexmedetomidine administration. 
Atipamezole is a potent, specific antagonist of both centrally and peripherally located α -
adrenoceptors. It is frequently used to reverse the sedation and cardiopulmonary effects induced by 
e.g. medetomidine in various animal species (Vainio & Vähä-Vahe, 1990; Raekallio et al., 1991; 
Arnemo & Søli, 1993b; 1995; Ko & McGrath, 1995; Ranheim et al., 1998; 1999; 2000b; Granholm 
et al., 2007; Rioja et al., 2008). However, no reports have yet been published on the interaction 
between atipamezole and vatinoxan in sheep sedated with α -adrenoceptor agonists. Thus, it was 
hypothesized that both antagonists would improve the cardiopulmonary performance in sheep sedated 
with medetomidine or a combination of medetomidine and ketamine. Additionally, it was postulated 
that the presence of vatinoxan would decrease the plasma concentration of medetomidine, which 
could hasten the recovery after atipamezole administration and prevent any resedation.  




2 REVIEW OF LITERATURE  
2.1 Alpha2-adrenoceptors: Classification, localization, and function  
Adrenergic receptors (adrenoceptors) are membrane-bound receptors that mediate various 
physiological effects via adrenaline, noradrenaline, and their analogues. Although adrenoceptors are 
structurally related, they have been classified into two subtypes (α and β) based on their relative 
responsiveness to natural and synthetic amines (Ahlquist, 1948). Later, the α-adrenoceptors were 
subdivided into α1 and α2 classes according their anatomical location, pre- or post-synaptic 
respectively (Langer, 1974). Alternatively, Berthelsen & Pettinger (1977) proposed a functional 
classification, where α1-adrenoceptors mediate excitatory responses and α2-adrenoceptors mediate 
inhibitory effects. Presently, the pharmacological classification of α-adrenoceptors, based on the 
affinity of each receptor for various agonists and antagonists, is widely accepted (Ruffolo et al., 1991). 
The α2-adrenoceptors are further subdivided into three subtypes α2A, α2B, and α2C (Lorenz et al., 1990; 
Blaxall et al., 1991; Bylund, 1992; Bylund et al., 1994; Zhong & Minneman, 1999). A fourth subtype, 
α2D, was identified in rat submaxillary (Michel et al., 1989) and bovine pineal glands (Simonneaux et 
al., 1991), albeit now considered to be a species homologue of human α2A subtype (Lanier et al., 
1991; Blaxall et al., 1993). On the other hand, α1-adrenoceptors are subdivided into α1A, α1B, and α1D 
(Docherty, 2010). A fourth type, named α1L, has been identified based on its low affinity for prazosin 
and other α1-antagonists (Flavahan & Vanhoutte, 1986; Hieble, 2007). For β-adrenoceptors, Lands et 
al. (1967) initially subdivided them into β1 and β2 subtypes. Later, a third subtype, β3, was identified 
when its encoding gene was isolated by Emorine et al. (1989), and a fourth type has been also been 
proposed by Hieble (2007).      
Pre-synaptic alpha2-adrenoceptors are G-protein coupled and their stimulation inhibit adenylyl 
cyclase activity through the Gi protein, leading to a decrease in the concentration of  cyclic adenosine 
3’, 5’-monophospate (cAMP) within the cell, thus decreasing the phosphorylation of regulatory 
proteins  (Pichot et al., 2012). Efflux of potassium ions through calcium-activated channels prevents 
calcium entry into the nerve terminal resulting in an inhibitory effect on secretion of neurotransmitters 
into the synaptic cleft (Hayashi & Maze, 1993; Piascik et al., 1996) and reduces activity of 
noradrenergic pathways (Carollo et al., 2008). However, α2-adrenoceptors are ubiquitously 
distributed within the mammalian tissues and organs, both pre, post- and extra-synaptically. With α2A 
being densely expressed within the locus coeruleus (Scheinin et al., 1994; MacDonald & Scheinin, 
1995), it is the predominant subtype in dog and rat brainstems (Schwartz et al., 1999). In sheep 
brainstems, α2D, a homologue of α2A, is the predominant subtype (Schwartz & Clark, 1998). Alpha2A 
mediates sedation and antinociception (Hunter et al., 1997; Lakhalani et al., 1997), anesthetic sparing 
effects (Lakhalani et al., 1997; Kable et al., 2000), temperature homeostasis (Hunter et al., 1997; 
Kable et al., 2000), spinal analgesia (Stone et al., 1997), and hyperglycemia (Fagerholm et al., 2004). 
The α2B receptors are primarily located in peripheral tissues, particularly in vascular smooth muscle 
fiber, thus mediating the vasoconstrictive response to agonist drugs (Docherty & McGrath, 1980; 
Link et al., 1996; Makaritsis et al., 1999; Kamibayashi & Maze, 2000; Paris et al., 2003). The 
peripherally located α2C subtype receptors contribute to vasoconstriction of small arteries (Chotani et 
al., 2004), whereas the centrally located ones are involved in the hypothermic response to α2-
adrenoceptor agonists and regulate dopamine-mediated effects in the brain (Sallinen et al., 1997; 
Björklund et al., 1999; Scheinin et al., 2001). On the other hand, postsynaptic α1-adrenoceptors are 




widely distributed in vascular smooth muscle, α1A being the predominant receptor mediating the 
vasoconstriction in many arteries such as mammary, mesenteric, splenic, hepatic, omental, renal, 
pulmonary, and the epicardial coronary ones (Rudner et al., 1999). It is also present in veins such as 
the caval, saphenous, and pulmonary veins (Michelotti et al., 2000). The α1B receptor subtype is the 
most abundant subtype in the heart, but is present at a low density (Brodde & Michel, 1999), whereas 
the α1D receptor subtype is the predominant receptor causing vasoconstriction in the largest arteries 
(Piascik et al., 1995; 1997) such as the aorta (Deng et al., 1996).  
2.1.1 Cardiovascular regulation via -adrenoceptors 
Alpha-adrenoceptors play a major role in regulation of vasomotor tone (Piascik et al., 1996). In vitro 
studies demonstrated that α1-adrenoceptors mediate vasoconstriction in both arterial and venous 
tissue preparations (Guimaraes & Moura, 2001; Docherty, 2010). Alpha2B-receptors, on the other 
hand, are the main subtypes mediating the arterial vasoconstriction (Link et al., 1996; Makaritsis et 
al., 1999). However, the peripheral α2A and α2C receptors are also involved in vasoconstriction of 
distal arteries (Guimaraes & Moura, 2001). The induced peripheral vasoconstriction increases the 
systemic vascular resistance (SVR) and evokes the baroreceptor reflex arch, which results in 
bradycardia as demonstrated in autonomically intact dogs (Bloor et al., 1992; Flacke et al., 1993). 
Similar outcomes have been reported after selective α1-adrenoceptor agonism by e.g. phenylephrine 
(Morimatsu et al., 2012). In autonomically denervated dogs the increase in afterload, without 
bradycardia, was responsible for the decreases in cardiac index (CI) (Flacke et al., 1990). 
Furthermore, the vasoconstriction of coronary arteries due to activation of α2-adrenoceptors may 
induce myocardial dysfunction as a result of decreased oxygen delivery (Flacke et al., 1993), although 
this may at least partially be prevented by a decrease in myocardial oxygen demand (Willigers et al., 
2006).  Interestingly, despite their absence in both myocardium and sinoatrial nodes, α2-adrenoceptor 
agonists produced indirect myocardial depressant effects in isolated heart preparations (Flacke et al., 
1992; Hongo et al., 2016). However, postsynaptic β1-receptors are the predominant adrenergic 
receptors within the myocardium, in the non-failing human heart representing approximately 80% of 
the expressed β-receptor population while the β2-subtype accounts for the remaining 20% (Bristow 
et al., 1986; 1991). Generally, activation of myocardial β1-adrenoceptors results in a positive inotropic 
and chronotropic response with little to no direct involvement from α-adrenoceptors. 
Simultaneously, activation of centrally located α2A-adrenoceptors decreases the sympathetic outflow 
and leads to a centrally mediated hypotensive effect (MacMillan et al., 1996; Altman et al., 1999), 
while inhibition of sympathetic transmission due to activation of presynaptic α2-receptors in 
sympathetic ganglia may also contribute (McCallum et al., 1998). Consequently, it can be concluded 
that activation of α2-adrenoceptors results in a biphasic blood pressure response: an initial 
hypertensive phase that is induced by α2B receptors followed by a longer lasting decrease in blood 
pressure, predominantly mediated by both the baroreflex-mediated bradycardia and central 
sympatholysis. 
2.2 Alpha2-adrenoceptor agonists 
Alpha2-adrenoceptor agonists, such as xylazine, detomidine, medetomidine, dexmedetomidine, and 
romifidine, represent a very commonly used class of sedatives in veterinary clinical practice. They 
induce dose-dependent sedation, analgesia, and skeletal muscle relaxation that can be reversed via 




administration of selective α2-adrenoceptor antagonists. Except for xylazine, which is a thiazine 
derivative, all other α2-adrenoceptor agonists and some antagonists have an imidazoline chemical 
structure. None of the clinically relevant α2-adrenoceptor agonists is defined to be subtype specific. 
Alpha2-adrenoceptor agonists are frequently combined with certain other sedatives, analgesics and/or 
anesthetics. 
2.2.1 Xylazine 
Xylazine (N-[2,6-dimethylphenyl]-5,6-dihydro-4H-1,3-thiazin-2-amine) was the first α2-
adrenoceptor agonist used in veterinary medicine. Xylazine has a 160 α2/α1-selectivity ratio for α-
adrenoceptors (Virtanen et al., 1988), but it is 10–20 times more potent in ruminants than in other 
species (Kästner, 2006). The first published study in English on xylazine in animals was by Clarke & 
Hall (1969). Since then, numerous studies describing its pharmacodynamic and pharmacokinetic 
properties in various animal species have been published in the veterinary literature. In sheep, for 
instance, xylazine’s sedative, analgesic, and pre-anesthetic effects have been extensively reported 
(Mitchell & Williams, 1976; Shokry et al., 1976; Hsu et al., 1987; 1989; Nolan et al., 1987; Kock, 
1991; Papazoglou et al., 1994; Celly et al., 1997a; 1999a; Aminkov et al., 2002; Grant & Upton, 
2004). Further, its combinations with agents such as ketamine and opioids have also been investigated 
in sheep (Nowrouzian et al., 1981; Green et al., 1981; Wright, 1982; Byagagaire & Mbiuki, 1984; 
Coulson et al., 1989; Lin et al., 1994; 1997; Hughan et al., 2001; Aminkov et al., 2002; Özkan et al., 
2010; de Carvalho et al., 2016).  
2.2.2 Detomidine 
Detomidine (4-[2,3-dimethylbenzyl]-1H-imidazole) is an α2-adrenoceptor agonist with an α2/α1 
selectivity ratio of 260 (Virtanen et al., 1988), developed primarily to be used in horses and cattle. 
Therefore, there is a limited number of published reports regarding its clinical use in sheep. 
Nevertheless, detomidine’s sedative effects have been reported in sheep after IV administration 
(Waterman et al., 1987), IM and IV (Singh et al., 1994) and constant rate infusion (de Moura et al., 
2018). Additionally, its analgesic (Haerdi-Landerer et al., 2003) and cardiopulmonary (Celly et al., 
1997a) effects were also investigated in sheep.    
2.2.3 Romifidine 
Romifidine (N-[2-bromo-6-fluorophenyl]-4,5-dihydro-1h-imidazol-2-amine), developed from 
clonidine (another α2-adrenoceptor agonist seldomly reported in the veterinary literature), is a 
selective α2-adrenoceptor agonist with an α2/α1 ratio of 340. Similarly to detomidine, romifidine is 
labeled mainly for sedation and premedication in horses, and it has all the usual properties of α2-
agonists. In one previous sheep study (Celly et al., 1997a), the degree of sedation and hypoxemia 
induced by IV romifidine (50 μg/kg) was comparable with that for xylazine (150 μg/kg IV), 
detomidine (30 μg/kg IV), or medetomidine (10 μg/kg IV).    
2.2.4 Medetomidine and dexmedetomidine  
Medetomidine (4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole) is an equal racemic mixture of two 
optical enantiomers, dexmedetomidine and levomedetomidine. The effects of medetomidine are 
attributed to the dextroenantiomer, while levomedetomidine is considered to be pharmacologically 
inactive (MacDonald et al., 1991; Savola & Virtanen, 1991; Kuusela et al., 2000). Medetomidine and 




dexmedetomidine are the most potent α2-adrenoceptor agonists in veterinary practice, with an α2/α1 
selectively ratio of 1620 reported for the racemic mixture (Virtanen et al., 1988). 
2.2.5 ST-91 
ST-91 (2-[(2,6-diethylphenylimino]-2-imidazolidine) is a hydrophilic derivative of clonidine, and it 
does not cross the blood-brain barrier (Kobinger & Pichler, 1975). Thus, it’s mainly used as a model 
drug in experimental studies (Kästner, 2006). In sheep, ST-91 (3–30 μg/kg IV) did not produce any 
sedation, but it did induce a dose-related decrease in partial pressure of arterial oxygen (PaO2) and 
heart rate (HR), also increasing mean arterial pressure (MAP) (Eisenach, 1988). Similarly, in 
halothane-anesthetized sheep receiving ST-91 (1.5–12 μg/kg IV), dose-dependent cardiopulmonary 
changes were observed (Celly et al., 1999b). Additionally, in conscious sheep, ST-91 (30 μg/kg IV) 
and clonidine (15 μg/kg IV) induced comparable cardiopulmonary responses (Celly et al., 1997b). 
Although the hypoxemic effects were less pronounced after ST-91 than after the centrally acting α2-
adrenoceptor agonists clonidine (Eisenach, 1988, Celly et al., 1997b) and medetomidine (Celly et al., 
1999b), the induced pulmonary hypertension after ST-91 was longer-lasting than with medetomidine 
(Celly et al., 1999b). It is worth considering, however, that the doses used in these studies were not 
necessarily equipotent which makes direct comparisons between studies and the various agonists 
challenging. 
2.2.6 Cardiopulmonary effects   
Alpha2-adrenoceptor agonists, regardless of their receptor affinity, induce various degrees of arterial 
hypoxemia in many ruminant species. The magnitude of the induced hypoxemia depends on factors 
such as the agonist dose and its route of administration, age, species, breed, and individual sensitivity, 
although sheep appear to be predisposed. Clinically, a wide range of respiratory symptoms have been 
reported, such as wheezy breathing with increased dyspnea associated with strong bubbling sounds 
on auscultation of the lungs (Uggla & Lindqvist, 1983), tachypnea (Hsu et al., 1987; 1989; Ko & 
McGrath, 1995; Celly et al., 1997a, b), decrease in respiratory frequency (Shokry et al., 1976; 
Mohammad et al., 1995; 1996), or no change (Borges et al., 2016). 
In sheep, xylazine caused a severe reduction in PaO2 after IV administration either to anesthetized 
(Aziz & Carlyle, 1978) or conscious animals (Celly et al., 1997a; Bacon et al., 1998). Likewise, IV 
medetomidine (5, 10, and 20 μg/kg) administered to conscious sheep led to a profound, dose-
dependent decrease in PaO2 (Bryant et al., 1996). In adult, conscious, spontaneously breathing sheep, 
xylazine (150 μg/kg), romifidine (50 μg/kg), detomidine (30 μg/kg), and medetomidine (10 μg/kg) 
induced a similar degree of hypoxemia after IV administration (Celly et al., 1997a). Similarly, IV 
xylazine (50 μg/kg) and detomidine (10 μg/kg) caused a pronounced hypoxemia in sheep, which was 
completely prevented by pre-treatment with idazoxan (100 μg/kg IV), an α2-adrenoceptor antagonist 
(Waterman et al., 1987). Conversely, in one-month-old lambs sedated with medetomidine (30 μg/kg 
IV), neither significant changes in PaO2 nor partial pressure of arterial carbon dioxide (PaCO2) were 
evident; with the arterial hemoglobin oxygen saturation percentage (SaO2) remaining above 90%. 
Neither IV atipamezole (30 or 60 μg/kg) nor yohimbine (1 mg/kg), both α2-adrenoceptor antagonists, 
altered the arterial oxygen tension (Ko & McGrath, 1995). Furthermore, for adult sheep sedated with 
medetomidine (30 μg/kg IM), PaO2 remained within physiologically acceptable limits, albeit reduced 
from the baseline level (Kästner et al., 2003).  




The hypoxemic effect of α2-agonists in sheep is mainly mediated via the peripheral α2-adrenoceptors 
(Celly et al., 1997b). However, the exact underlying mechanisms remain unresolved, although several 
theories have been proposed. Xylazine caused contraction of isolated sheep tracheal strips 
(Papazoglou et al., 1995) and increased airway pressure in halothane-anaesthetized sheep (Nolan et 
al., 1986a; Papazoglou et al., 1994). The authors speculated that the increased airway pressure was 
due to decreased dynamic compliance and/or increased airway resistance (Nolan et al., 1986a, 
Papazoglou et al., 1994). In addition, pulmonary edema formation as a result of platelet aggregation 
and pulmonary microembolism (Eisenach, 1988), pulmonary venoconstriction (Bacon et al., 1998), 
the release of inflammatory mediators due to the activation of intravascular pulmonary macrophages 
(Celly et al., 1999a) and increased hydrostatic pressure (Kästner et al., 2007) have been suggested to 
be the cause of hypoxemia. In sevoflurane-anesthetized sheep, dexmedetomidine markedly decreased 
dynamic compliance, and increased airway resistance, pulmonary shunt fraction and dead space 
ventilation (Kästner et al., 2005; 2007; Kutter et al., 2006). Furthermore, a severe bilateral edema was 
observed in computed tomography (CT) images of the ventral lung field, where the lung density was 
sharply increased 9–12 minutes after dexmedetomidine (2 μg/kg IV) administration in sevoflurane-
anesthetized sheep (Kästner et al., 2007). Additionally, necropsy samples collected 10 minutes after 
dexmedetomidine administration revealed subpleural hemorrhage and the lungs appeared heavy with 
abundant amounts of blood drained from the excised tissue, while the trachea was filled with foamy 
fluid (Kästner et al., 2007). On histopathological examination, an eosinophilic alveolar edema 
associated with capillary congestion and extravasation of erythrocytes was detected (Kästner et al., 
2007). Similar histopathological changes were also observed in sheep lungs 10 minutes after 
treatment with either xylazine (150 μg/kg IV) or ST-91 (30 μg/kg IV) (Celly et al., 1999a), and at 30 
minutes after IV xylazine (200 μg/kg) (Bacon et al., 1998). An electron microscopic examination 
three minutes after xylazine was given revealed a mild pulmonary interstitial edema and after 10 
minutes, extensive endothelial damage with interstitial and alveolar edema was evident (Celly et al., 
1999a). Interestingly, with ST-91, alveolar edema and capillary endothelial damage were detected 
already after only three minutes (Celly et al., 1999a). 
The cardiovascular effects of α2-adrenoceptor agonists are very similar amongst various mammalian 
species (Greene & Thurmon, 1988; Murrell & Hellebrekers, 2005). Intravenous administration of α2-
adrenoceptor agonists typically lead to a biphasic blood pressure response, characterized by an initial 
hypertension followed by normo- or hypotension, accompanied by a profound bradycardia (Aziz & 
Carlyle, 1978; Savola, 1989; Vainio, 1989; Vainio & Palmu, 1989), reduced cardiac output (CO), 
increased central venous pressure (CVP) and SVR (Pypendop & Verstegen, 1998; Honkavaara et al., 
2011; Rolfe et al., 2012). In sheep, IV administration of medetomidine (5, 10 and 20 μg/kg) resulted 
in decrease in HR and significant increase in MAP, the duration of which was dose-dependent. 
Cardiac output decreased after all three doses and remained reduced throughout a 60-minute 
observation period (Bryant et al., 1996). A target-controlled infusion of medetomidine (0.8, 1.6, 3.2, 
6.4, and 12.8 ng/mL target concentrations) in awake sheep caused concentration-related reductions 
in HR and CO, and an increase in MAP (Talke et al., 2000). In sheep treated with ST-91, lacking 
central activity, the induced systemic and pulmonary hypertension were more pronounced and long 
lasting than after clonidine (Eisenach, 1988; Celly et al., 1997b) or medetomidine (Celly et al., 1999b) 
and occurred with a smaller dose than was required to produce pulmonary alterations (Celly et al., 
1999b). In sheep, systemic hypotension (MAP < 60 mmHg) has not been reported after IV 




administration of various α2-adrenoceptor agonists. Although in one study (Bryant et al., 1996), some 
sheep may have had MAP values below 60 mmHg one hour after IV medetomidine (10 and 20 μg/kg), 
in most other investigations in sheep hypotension, expected to occur towards to end of the 
observational periods, was not observed (Celly et al., 1997a; de Carvalho et al., 2016; Borges et al., 
2016). 
The intensity of the cardiovascular response to α2-adrenoceptor agonists probably depends on the 
route of administration. For instance, in humans, IV dexmedetomidine (2 μg/kg) caused a 10% 
decline in HR and 22% rise in MAP within five minutes of starting the infusion, but when the same 
dose was given IM, the changes in HR and MAP were less obvious (Dyck et al., 1993). Further, the 
dose also seems to account for the magnitude of induced cardiovascular effects in sheep. For example, 
only minor changes were observed in hemodynamics following IV administration of xylazine (150 
μg/kg) (Doherty et al., 1986; Celly et al., 1997a), whereas marked cardiovascular changes were 
produced after a higher dose (500 μg/kg IV) in sheep (Aziz & Carlyle, 1978). However, the small 
number of animals used by Celly et al. (1997a) might also account for the lack of statistically 
significant differences, while in the other report by Doherty et al. (1986) the very low PaCO 2 could 
have attenuated the vasoconstrictive effects of xylazine, whereas the severe hypoxemia (PaO2 < 40 
mmHg) reported by Aziz & Carlyle (1978) might have had an opposite effect.         
Reports on the effects of α2-adrenoceptor agonists on the ovine pulmonary vasculature are somewhat 
inconsistent. In halothane-anesthetized, spontaneously breathing sheep, increasing the dose of 
medetomidine (0.5, 1, 2, and 4 μg/kg IV) were followed by statistically insignificant increases in 
mean pulmonary arterial pressure (MPAP), pulmonary vascular resistance (PVR), and pulmonary 
Arterial occlusion pressure (PAOP) when compared with saline-treated sheep (Celly et al., 1999b). 
Likewise, in conscious sheep receiving target-controlled infusions of medetomidine, no significant 
changes were detected in PAOP or MPAP, although PVR increased (Talke et al., 2000). Conversely, 
marked increases in MPAP and PAOP were observed following IV administration of 
dexmedetomidine (2 μg/kg) in mechanically ventilated, sevoflurane-anesthetized sheep (Kästner et 
al., 2007). Nevertheless, in a similar study setting, an equal dexmedetomidine dose did not cause 
significant changes in PVR or PAOP despite the significant increase in MPAP (Kutter et al., 2006). 
In general, the large inter-individual variation and small sample sizes might partially account for both 
the lack of statistically significant changes and some of the discrepancies in outcomes between 
apparently identically conducted investigations. For instance, in the aforementioned study, as only 4 
sheep were studied, no significant differences were reached in PVR, although it increased from 85 ± 
27 at baseline to 144 ± 82 dynes.sec/cm5 (Kutter et al., 2006).  
2.2.7 Central effects 
The sedative effects of α2-adrenoceptor agonists are mainly mediated via the α2A receptors located in 
the locus coeruleus of the brainstem (Doze et al., 1989; Correa-Sales et al., 1992). The sedative 
properties of medetomidine were first demonstrated in mice and rats by Virtanen (1985) and in chicks 
by Savola et al. (1986). In domestic sheep, the use of medetomidine (25 μg/kg) was first reported as 
an IM combination with ketamine (1 mg/kg) by Laitinen (1990). The combination reportedly 
provided sufficient anesthesia for mandibular surgery, and with an induction time of 8.8 ± 3.6 minutes 
all the animals exhibited relaxation of limbs, jaws and neck muscles (Laitinen, 1990). Later, 
Mohammad et al. (1993) described the sedative and analgesic effects of medetomidine (40 μg/kg IM) 




in Awassi sheep. Sedation was evident after nine minutes, recumbency occurred at 17 minutes and 
lasted for 58 minutes on average, respectively (Mohammad et al., 1993). In sheep receiving 
medetomidine (30 μg/kg IM) the sedative effects were apparent within 5 minutes and the maximum 
effect detected between 30-40 minutes after injection (Kästner et al., 2003). When the same dose was 
given IV to lambs, all animals became recumbent within 1–2 minutes and remained so for 73 ± 6.8 
minutes (Ko & McGrath, 1995). In adult sheep, 40 μg/kg of IV medetomidine produced sternal 
recumbency 7 minutes after injection, although the authors suggested that this considerably long lag 
period was because some of the animals supported themselves against a pen wall for several minutes 
(Ranheim et al., 2000b). Elsewhere, premedication with IV dexmedetomidine (5 μg/kg) and 
medetomidine (10 μg/kg) had similar effects on both isoflurane-sparing and cardiopulmonary 
function in sheep undergoing orthopedic surgery (Kästner et al., 2001b). Similarly, no differences in 
isoflurane requirements after equipotent IM doses of dexmedetomidine (15 μg/kg) or medetomidine 
(30 μg/kg) were observed. However, HR was significantly higher with dexmedetomidine (Kästner et 
al., 2001a).  
The antinociceptive effects of medetomidine and dexmedetomidine have been demonstrated in 
various animal species including rats (Vickery et al., 1988), dogs (Vainio et al., 1989; Tyner et al., 
1997; Bennett et al., 2016), sheep (Muge et al., 1994), and cats (Ansah et al, 1998; 2000). When 
compared with buprenorphine, methadone, and flunixin meglumine, xylazine was the only agent that 
showed a significant analgesic effect in relieving acute pain induced by electric stimulation applied 
to lower hind limbs (Grant et al., 1996). Furthermore, xylazine (50 μg/kg IV) produced profound 
antinociception to both mechanical and thermal stimuli in healthy sheep (Nolan et al., 1986b; 1987), 
although its analgesic potency was significantly reduced in sheep suffering from chronic pain due to 
foot rot (Ley et al., 1991). Similarly, clonidine (6 μg/kg IV) produced antinociceptive activity to 
thermal and mechanical stimuli, which was more potent and longer lasting than that achieved with 
xylazine (50 μg/kg IV) in sheep (Nolan et al., 1987). Medetomidine, likewise, produced a dose-
dependent antinociceptive effect to mechanical stimulation in sheep after IV administration, with all 
of the tested doses (1–7 μg/kg), except the lowest one, significantly raising the areas under the time-
response curves when compared to the baseline or a saline control (Muge et al., 1994).     
2.2.8 Other effects 
Alpha2-adrenoceptor agonists are known to induce hyperglycemia associated with hypoinsulinemia 
in several animal species (Metz et al., 1978; Eichner et al., 1979; Benson et al., 1984; Ambrisko & 
Hikasa, 2003; Restitutti et al., 2012; Pakkanen et al., 2018; Kallio-Kujala et al., 2018c). Stimulation 
of pancreatic α2A-adrenoceptor inhibits insulin release and consequently increases plasma glucose 
(Fagerholm et al., 2004; 2008). In sheep, xylazine administration (160 μg/kg IV) led to a 4-fold 
increase in plasma glucose in the following 20 minutes (Muggaberg & Brockman, 1982), which was 
associated with hypoinsulinemia (Brockman, 1981; Muggaberg & Brockman, 1982). In some species, 
e.g. cattle and goats, glucose was also detected in the urine of xylazine or medetomidine-treated 
animals (Thurmon et al., 1978; Raekallio et al., 1994). For sheep, to the authors’ knowledge, there is 
no available reports suggesting whether or not the α2-adrenoceptor agonists-evoked hyperglycemia 
might be associated with glycosuria. Furthermore, medetomidine (40 μg/kg IV) induced two phases 
of hyperglycemia in sheep: the glucose concentration increased immediately after medetomidine, and 
then stabilized before a secondary surge, which reached its peak at 240 minutes. Reversal with 




atipamezole (200 μg/kg IV), administered 60 minutes after medetomidine, prevented the later 
hyperglycemic phase (Ranheim et al., 2000a). In cattle, on the other hand, medetomidine (40 μg/kg 
IV) induced marked hyperglycemia, which peaked almost two hours after the treatment (Ranheim et 
al., 2000a). 
Alpha2-adrenoceptor agonists have been shown to increase urine production in several animal species, 
including cattle (Thurmon et al., 1978), horses (Thurmon et al., 1984), ponies (Trim & Hanson, 1986), 
goats (Raekallio et al., 1994), dogs (Burton et al., 1998, Saleh et al., 2005; Talukader & Hikasa, 2009), 
and cats (Murahata & Hikasa, 2012). In cattle, for instance, urine output was almost 10-fold higher 
during the first hour following IM xylazine 0.44 mg/kg and further increase to approximately18-fold 
in the second hour when compared to the control animals (Thurmon et al., 1978). Several factors have 
been suggested to be involved in this diuretic effect, including inhibition of antidiuretic hormone 
secretion from the pituitary gland (Roman et al., 1979; Cabral et al., 1998) and a consequent reduction 
in its plasma concentrations (Saleh et al., 2005; Talukader & Hikasa, 2009), inhibition of renin release 
in the kidneys (Smyth et al., 1987), inhibition of renal sympathetic activity (Menegaz et al., 2000), 
osmotic diuresis due to hyperglycemia (Thurmon et al., 1978; Burton et al., 1998), and inhibition of 
tubular sodium reabsorption (Gesek & Strandhoy, 1990). Administration of yohimbine and 
atipamezole antagonized medetomidine-induced diuresis in dogs (Talukder et al., 2009). On the other 
hand, in mice, vatinoxan failed to inhibit a dexmedetomidine-induced increase in voiding (Aro et al., 
2015). 
In sheep, xylazine dose-dependently decreased ruminal motility after both IV (Toutain et al., 1982) 
and IM (Mohammed et al., 1996) injections, although an early increase in food intake in sheep was 
observed (Mohammed et al., 1996). Furthermore, detomidine (10–40 μg/kg IV), xylazine (20–80 
μg/kg IV), and clonidine (2.5–10 μg/kg IV) ceased both the primary and secondary contractions of 
the rumen, resulting in ruminal bloating which was effectively reversed by the α2-adrenoceptor 
antagonists yohimbine (200 μg/kg IV) and tolazoline (400 μg/kg IV) in sheep (Ruckebush & Allal, 
1987).  
2.2.9 Pharmacokinetic properties  
The studies describing the pharmacokinetics of α2-adrenoceptor agonists in sheep are limited. Garcia-
Villar et al. (1981) compared the pharmacokinetics of xylazine after IV and IM injections in four 
species: cattle, sheep, horses, and dogs. The data showed remarkably small interspecies differences, 
the elimination half-life (T½) was about 23 minutes following both IV and IM administration of 
xylazine (1 mg/kg) in sheep (Garcia-Villar et al., 1981). After IM administration, the maximum 
plasma concentration (Cmax) of 0.13 μg/mL was reached after 14.7 minutes (Tmax), while the 
bioavailability was 40.8 ± 23.4% (Garcia-Villar et al., 1981). For medetomidine, the apparent volume 
of distribution (VZ) was 2.7 L/kg following IV administration of 15 μg/kg and the T½ was 
approximately 37 minutes, relatively short when compared to non-ruminant species and rationalized 
by a relatively high clearance (CL) of 57.5 mL/kg/min (Muge et al., 1996). Similar results were 
reported for sheep receiving a higher medetomidine dose (40 μg/kg IV) with a steady state volume 
of distribution (Vdss) of 1.8 L/kg, elimination half-life of approximately 35 minutes and clearance of 
44.2 mL/kg/min (Ranheim et al., 2000b). Following IM administration of medetomidine (30 μg/kg) 
in sheep, the Cmax was 4.9 ng/mL with Tmax being 29.2 min, while the Vdss, T½ and CL were 3.9 L/kg, 
32.7 min, and 81 mL/kg/min, respectively (Kästner et al., 2003). The pharmacokinetics of dex- and 




levomedetomidine have also been compared in sevoflurane-anesthetized sheep: the CL of the 
dextroisomer was significantly smaller (Kästner et al., 2006), possibly since levomedetomidine is less 
likely to affect its own disposition as it does not produce relevant cardiovascular effects (Dutta et al., 
2000). Elsewhere, medetomidine was not detected in plasma following esophageal administration (15 
μg/kg), suggesting a low bioavailability due to the high first pass metabolism in the liver after enteral 
administration (Hyndman et al., 2015).  
2.3 Ketamine and its use with 2-adrenoreceptor agonists in sheep 
Ketamine (2-[ 2-chlorophenyl]-2-[methylamino]cyclohexan-1-one), a racemic mixture of S- and R-
ketamine, “induces a dissociative or cataleptoid anesthesia in which the eyes remain open with a slow 
nystagmic gaze, varying degrees of hypertonus and purposeful or reflexive skeletal muscle 
movements often occur unrelated to surgical stimulation” (White et al., 1982). In sheep, this cataleptic 
state was first described by Thurmon et al. (1973), who used ketamine as a sole anesthetic agent. 
Irrespective of the dose (22–44 mg/kg) or route of administration (IV and IM), the eyes remained 
open with nystagmus and the movements of limbs were not associated with painful stimulations. The 
anesthetic and analgesic effects of IV ketamine in sheep seemed to be dose-dependent, as 2 mg/kg 
induced only ataxia and sternal recumbency while increasing the dose (5, 11.6 and 22 mg/kg IV) led 
to prolongation of anesthesia (Waterman & Livingston, 1978). In addition, salivation (Thurmon et 
al., 1973; Britton et al., 1974; Waterman & Livingston, 1978), mild regurgitation, and protrusion of 
tongue (Thurmon et al., 1973) were also observed. In contrast, in pregnant ewes receiving a smaller 
dose of ketamine (2 mg/kg IV) followed by continuous IV infusion, no salivation was noted (Taylor 
et al., 1972). Furthermore, in unpremedicated sheep and goats, ketamine (2 mg/kg IV) resulted in 
rapid recumbency associated with poor muscle relaxation, inconsistent analgesia, strongly maintained 
swallowing, pharyngeal and eructive reflexes, and poor conditions for orotracheal intubation (Green 
et al., 1981). Therefore, ketamine is typically not recommended to be used as a sole anesthetic in 
ruminants. The major metabolite of ketamine, norketamine, appears to retain about one-fifth to one-
third of ketamine’s activity in rodent models (Ebert et al., 1997; Holtman et al., 2008). 
Co-administration of ketamine with agents that improve muscle relaxation, such as benzodiazepines 
and α2-adrenoreceptor agonists, is recommended. For instance, premedication with xylazine (200 
μg/kg IM) effectively reduced some of the undesirable effects of ketamine (22 mg/kg IV), such as 
muscle rigidity, ataxia, and insufficient suppression of reflexes in sheep (Nowrouzian et al., 1981). 
Likewise, satisfactory surgical conditions were achieved in sheep following pre-administration of 
xylazine (100 μg/kg IM) or diazepam (2 mg/kg IV) 10 and 15 minutes before ketamine (4 m/kg IV) 
respectively (Green et al., 1981). However, xylazine (100 μg/kg) in combination with ketamine (7.5 
mg/kg) produced a longer lasting effective anesthesia than when the same dose of ketamine was 
combined with diazepam (0.375 mg/kg) IV (Coulson et al., 1989). Further, onset of anesthesia was 
significantly faster in sheep when ketamine (22 mg/kg) was combined IM with xylazine (200 μg/kg) 
rather than diazepam (0.4 mg/kg) (Özkan et al., 2010).  
Consequently, ketamine is often combined with various α2-adrenoreceptor agonists. In domestic 
sheep, medetomidine (125 μg/kg) and ketamine (2.5 mg/kg) resulted in rapid immobilization within 
three minutes after IM administration, characterized by lack of response to auditory or physical 
stimulation (Caulkett et al., 1994). Similarly, simultaneous IM administration of medetomidine (25 




μg/kg) and ketamine (1 mg/kg) produced adequate anesthesia for mandible surgery as described 
earlier (Laitinen, 1990). After IV administration of medetomidine (20 μg/kg) and ketamine (2 mg/kg), 
sheep became sedated within 40 seconds, endotracheal intubation was easily performed after three 
minutes, and no limb rigidity or tremors were observed (Tulamo et al., 1995). Concomitant IM 
administration of ketamine (11 mg/kg) and xylazine (200 μg/kg) appeared to produce longer-lasting 
antinociception when compared with the IV route (Byagagaire & Mbiuki, 1984). Further, in non-
domestic small ruminants, ketamine combined with various α2-adrenoreceptor agonists is extensively 
used for reliable sedation and immobilization since the agonists alone appear insufficient (Jalanka & 
Roeken, 1990). Since the introduction of medetomidine into the veterinary market in the mid-1980s, 
its utility with ketamine for immobilization of non-domestic mammals has been extensively studied 
(Jalanka, 1988; 1989; 1990; Jalanka & Roeken, 1990; Tyler et al., 1990; Portas et al., 2003; Bush et 
al., 2004; Arnemo et al., 2005; 2011; 2013; Bouts et al., 2011; Evans et al., 2013).      
The cardiopulmonary effects of ketamine are characterized by indirect cardiovascular stimulation as 
a result of its sympathomimetic effects mediated within the CNS (Ivankovich et al., 1974), inhibition 
of neuronal uptake of catecholamines by sympathetic nerve endings (Salt et al., 1979) and an inotropic 
effect on the myocardium (Tweed et al., 1972; Gelissen et al., 1996). Although direct vasodilation 
has also been reported (Altura et al., 1980), HR and arterial blood pressure tend to elevate due to an 
increase in the overall sympathetic outflow (Wong & Jenkins, 1974). Accordingly, ketamine has been 
reported to increase HR both after IV and IM injections (Thurmon et al., 1973) and blood pressure 
after IV administration in sheep (Waterman & Livingston, 1978). However, prior administration of 
sedative or anesthetic agents, which reduce sympathetic outflow from the CNS and/or decrease the 
amount of circulating catecholamines, such as α2-adrenoreceptor agonists, could blunt the 
cardiovascular stimulatory effect of ketamine (Bidwai et al., 1975; Jackson et al., 1978; Bålfors et al., 
1983; Reich & Silvay, 1989). In sheep, IV co-administration of xylazine (100 μg/kg) and ketamine 
(7.5 mg/kg) resulted in an immediate, transient reduction in SVR, and significant decreases in MAP, 
CO and Hb when compared with pre-treatment values (Coulson et al., 1989). However, after 
medetomidine (125 μg/kg) combined with ketamine (2.5 mg/kg) IM, HR, CI, and DO2 were 
significantly decreased from the baseline while MAP (Caulkett et al., 1994; 1996), SVR, and PVR 
(Caulkett et al., 1996) increased, an outcome typical for α2-adrenoreceptor agonists. Rapid 
administration of ketamine IV has also been shown to induce brief respiratory depression in sheep 
(Levinson et al., 1973; Waterman & Livingston, 1978) followed by a longer period of stimulation 
(Waterman & Livingston, 1978). Suggestive of marked hypoventilation in animals breathing room 
air, ketamine caused a dramatic decrease in PaO2 and a significant increase in PaCO2 immediately 
after IV bolus administration. However, PaO2 returned to pre-treatment levels within 10 minutes and 
significantly exceeded it from 20 minutes onwards (Waterman & Livingston, 1978). While not 
observed in another study investigating IV ketamine in sheep (Thurmon et al., 1975), transient 
ventilatory suppression has been observed in other species as well, such as dogs (Gassner et al., 1974; 
Haskins et al., 1985), cats (Haskins et al., 1975), and humans (Waxman et al., 1980).  
2.4 Alpha2-adrenoceptor antagonists 
The effects of α2-adrenoreceptor agonists can be promptly reversed via administration of α2-
adrenoceptor antagonists, such as tolazoline, yohimbine, and atipamezole, many of which are licensed 
for veterinary use in several countries.  




Yohimbine is an indole alkaloid that comes from a number of plant sources. It is a potent α2-
adrenoreceptor antagonist with a 40:1 selectivity ratio for α2/α1 adrenoceptors (Virtanen et al., 1989). 
Yohimbine has mainly been used to reverse xylazine-induced sedation in many species, including 
sheep (Hsu, 1981; 1983; Hsu & Shulaw, 1984; Hsu et al., 1987; 1989; Jensen, 1985; Jessup et al., 
1985a, b; Kollias-Baker et al., 1993). However, it was less effective in reversing medetomidine-
induced sedation than atipamezole in one-month-old lambs (Ko & McGrath, 1995) as discussed later. 
Moreover, IV yohimbine (125 μg/kg) 20 minutes after IV xylazine (150 μg/kg) and in laterally 
recumbent sheep, did not produce a clinically desirable reversal: it abolished the induced paradoxical 
respiratory patterns, but the improvement in PaO2 took almost an hour (Doherty et al., 1986).     
Tolazoline is a synthetic non-selective α-adrenoceptor antagonist (Casbeer & Knych, 2013) used to 
reverse sedation induced by α2-adrenoreceptor agonists in ruminants (Takase et al., 1986; Hsu et al., 
1987; 1989; Powell et al., 1998) and horses (Carroll et al., 1997; Hubbell & Muir, 2006). Tolazoline 
has higher affinity for sheep brainstem receptors than the other α2-adrenoceptors, but compared with 
yohimbine and atipamezole, it has the lowest overall affinity for all α2-adreneroceptor subtypes 
(Schwartz & Clark, 1998). When IV yohimbine (0.2 mg/kg) and tolazoline (2 mg/kg) were given five 
minutes after xylazine (0.3 mg/kg IV) to 6 ewes, tolazoline shortened the duration of sedation from 
54 ± 5 minutes to 10 ± 2 minutes and reversed the decrease in PaO2 within 10 minutes, whereas 
yohimbine did not significantly change the duration of either the induced recumbency (being 42 ± 8 
minutes) or hypoxemia (Hsu et al., 1989). In another report by the same group (Hsu et al., 1987), 
using similar doses of tolazoline and yohimbine given IV 10 minutes after xylazine (0.4 mg/kg IV) 
to sheep, no significant differences were reported regarding sedation reversal, where both shortened 
the induced recumbency times from 41 minutes to 12 and 18 minutes on average, respectively (Hsu 
et al., 1987). The authors suggested that the difference in study protocols might account for this 
discrepancy, as the animals were confined to small pens in one study, but not in the other (Hsu et al., 
1989).   
2.4.1 Atipamezole 
Atipamezole (5-[2-ethyl-1,3-dihydroinden-2-yl]-1H-imidazole) is the most specific α2-
adrenoreceptor antagonist, with a selectivity ratio of 8526 for α2/α1 (Virtanen, 1989; Virtanen et al., 
1989). It reverses the centrally mediated sedative and analgesic effects induced by various α2-
agonists, for example in dogs (Clark & England, 1989; Vainio, 1990; Vainio & Vähä-Vahe, 1990; 
Granholm et al., 2007), horses (Raekallio et al., 1990; Luna et al., 1992; Yamashita et al., 1996; Di 
Concetto et al., 2007; Knych & Stanley, 2014), ruminants (Thompson et al., 1991; Arnemo & Søli, 
1993a, b; 1995; Mohammad et al., 1995; Ko & McGrath, 1995; Ranheim et al., 1998; 1999; 2000b; 
Rioja et al., 2008), and non-domesticated species (Jalanka, 1988; 1989; 1990; Tsuruga et al., 1999; 
Bush et al., 2004; Arnemo et al., 2005; 2011). Atipamezole is widely used in veterinary clinical 
practice to antagonize medetomidine-induced sedation and to manage inadvertent over-dosages, but 
it is not currently licensed for food-producing animals. In sheep, less than two minutes following 
atipamezole administration (200 μg/kg IV) given 60 minutes after medetomidine (40 μg/kg IV), all 
the animals regained a standing posture (Ranheim et al., 2000b). Further, both the recovery time and 
time to walking were significantly shorter after reversal with atipamezole than with yohimbine in 
lambs sedated with medetomidine, as stated above (Ko & McGrath, 1995). More specifically, animals 
treated with yohimbine (1 mg/kg IV) 15 minutes after medetomidine (30 μg/kg IV) remained laterally 




recumbent for about 12 minutes and did not walk unassisted until 16 minutes, on average, whereas 
with atipamezole (30 or 60 μg/kg IV) the animals walked unassisted within 3 minutes after reversal 
(Ko & McGrath, 1995). Atipamezole has a 100-fold higher affinity than yohimbine for the α2D 
receptor subtype, the predominant one in the ovine brainstem, thus it seems more effective in 
antagonizing sedation in this species as speculated by Schwartz & Clark (1998). However, a relapse 
in sedation (resedation), drowsiness and somnolence were observed after reversal with atipamezole 
in dogs (Vainio & Vähä-Vahe, 1990; Vähä-Vahe, 1990) and cattle (Ranheim et al., 1998; 1999). 
Nevertheless, for up to seven hours after reversal with atipamezole, no resedation has been reported 
in sheep (Ranheim et al., 2000b).  
In addition, atipamezole has been shown to be effective in reversing the peripheral effects of α2-
adrenoreceptor agonists as demonstrated in a number of species. Savola (1989) reported that 
atipamezole (10–300 μg/kg IV) completely restored HR and MAP when given during the most 
intense bradycardic and hypotensive phase induced by medetomidine in cats anesthetized with ether 
and chloralose (60 mg/kg IV). Later, Vähä-Vahe (1990) found that atipamezole reversed 
medetomidine-induced bradycardia in a dose-dependent manner in dogs. In sheep, atipamezole at a 
dose equal to five times that of the preceding medetomidine dose, reversed the reductions in HR, RR, 
and ruminal contractions (Mohammad et al., 1995). Moreover, in conscious, chronically instrumented 
sheep, when atipamezole was infused with a dose 2.5 times that of medetomidine, it significantly 
increased HR and reversed the increases in MAP, SVR, and PaCO2. However, it failed to restore 
PaO2 and PVR to pre-medetomidine levels (Talke et al., 2000). Additionally, pre-treatment with 
atipamezole prevented the xylazine-induced increase in airway pressure in halothane-anesthetized 
sheep (Papazoglou et al., 1994) and inhibited the contractile effect of xylazine on isolated sheep 
tracheal preparations (Papazoglou et al., 1995).  
The pharmacokinetic properties of atipamezole (250 μg/kg IM) have been investigated both alone 
and 30 minutes after medetomidine (50 μg/kg IM) in dogs (Salonen et al., 1995). When used alone, 
the Tmax and T½ were 0.25 ± 0.21 and 0.95 ± 0.40 h respectively, Cmax was 99.7 ± 35.1 ng/mL, Vz 
was 2.3 ± 1.12 L/kg, CL was 27.3 ± 4.9 mL/min/kg, and AUC was 156.7 ± 27.7 ng.h/mL (Salonen et 
al., 1995). Prior administration of medetomidine significantly altered the pharmacokinetics of 
atipamezole with Tmax and T½ being 0.41 ± 0.34 and 1.2 ± 0.53 h respectively, Cmax being 81.7 ± 16.7 
ng/mL, CL was 23.5 ± 4.1 mL/min/kg, and AUC was 182.1 ± 35.1 ng.h/mL (Salonen et al., 1995). 
This was attributed to medetomidine-induced reduction in cardiac output and, consequently, hepatic 
blood flow as speculated by Salonen et al. (1995). On the other hand, atipamezole significantly altered 
the pharmacokinetics of medetomidine when used for reversal of sedation, particularly in ruminants. 
In sheep, for instance, atipamezole (200 μg/kg IV) given 60 minutes after medetomidine (40 μg/kg 
IV) significantly increased the plasma concentrations of medetomidine by 1.8–3.1 fold, which 
prolonged its detection time in plasma by 30 minutes when compared with sheep receiving saline 
(Ranheim et al., 2000b). Furthermore, atipamezole significantly decreased medetomidine’s T½ from 
34.8 ± 7.3 to 21.8 ± 5.2 minutes, while no significant changes were detected in CL (44.2 ± 11.3 vs 
38.5 ± 4.3 mL/ min/kg), VZ (1.77 ± 0.26 vs 1.65 ± 0.19 L/kg), or AUC (953 ± 223 vs 1050 ± 115 
ng.min/mL) (Ranheim et al., 2000b). The authors reported comparable results in reindeer (Ranheim 
et al., 1997), dairy calves (Ranheim et al., 1998) and cows (Ranheim et al., 1999), and they speculated 
that atipamezole may have displaced medetomidine from the highly perfused tissues such as CNS, 
kidneys, liver, and lungs, thus increasing its concentration in plasma.                    





Vatinoxan, previously known as L-659,066 and MK-467, (N-[2-[(2R, 12bS)-2'-oxospiro 
[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,5'-imidazolidine]-1'-yl] ethyl] methane- 
sulfonamide) with a selectivity ratio of 105:1 for α2/α1 adrenoceptors. It has a low lipophilicity 
(octanol:phosphate buffer partition coefficient of 1.3), which could explain why it penetrates the 
blood-brain-barrier (BBB) poorly, limiting its pharmacodynamic effects mainly to peripheral organ 
systems (Clineschmidt et al., 1988). However, other agents e.g. morphine and hydromorphone have 
a comparable octanol:phosphate buffer partition coefficient (Avdeef et al., 1996), but they do 
penetrate the BBB. Thus, the molecular weight, ionization degree, presence of active transport efflux, 
or protein binding characteristics might also contribute to vatinoxan’s limited penetration through the 
BBB. For instance, the molecular weight for morphine is 285 g/moL while that of vatinoxan is 455 
g/moL. In mice, P-glycoprotein (P-gp) is involved in regulating the extent of morphine transport 
across the BBB (Xie et al., 1999). The transcellular movement of vatinoxan was assessed in two cell 
line models transfected with human P-gp, and the results revealed that vatinoxan has no apparent 
permeability in the apical-basolateral direction suggesting that it is not a P-gp substrate (Bennett et 
al., 2017b). However, the occurrence of basolateral-apical transport indicates that vatinoxan may be 
a substrate for an unknown cellular efflux mechanism other than P-gp (Bennett et al., 2017b).          
2.4.2.1 Cardiopulmonary effects  
In a dose-dependent manner, IV vatinoxan slightly decreased MAP and increased HR, where the 
latter was strongly associated with increasing plasma noradrenaline levels in conscious rats 
(Szemeredi et al., 1989). The effects on HR and MAP were attributed to the inhibition of presynaptic 
α2-adrenoreceptors and reflexive sympathetic activation due to blockade of α2-receptors on arterial 
smooth muscle (i.e. increase in HR to compensate the effects of vasodilation on MAP) (Szemeredi et 
al., 1989). In humans, a transient, insignificant increase in blood pressure with no effect on HR was 
observed (Warren et al., 1991; Schafers et al., 1992). In sheep, pre-treatment with vatinoxan (264 
μg/kg IV) failed to prevent the increase in MAP induced by the α1-adrenoceptor antagonist 
methoxamine (75 μg/kg IV), while no effect on HR was reported (Bryant et al., 1998). In dogs, 
vatinoxan increases HR, CO, MPAP, DO2 and oxygen consumption and decreases SVR after either 
a 10-minute IV infusion (Pagel et al., 1998) or when administered as a rapid IV bolus (Enouri et al., 
2008). Similarly, Honkavaara et al. (2011) reported a transient increase in HR, CI, and DO2 with a 
slight decrease in SVR, while MAP did not significantly differ from baseline values following IV 
administration of vatinoxan (250 μg/kg) in beagle dogs. Additionally, no significant changes were 
detected in PaO2, PaCO2, nor plasma lactate concentrations (Honkavaara et al., 2011). In cats, 
vatinoxan (600 μg/kg IV) increased HR and transiently increased MPAP while MAP, diastolic arterial 
pressure (DAP), and SVR decreased (Pypendop et al., 2017a). When the same dose was used IM in 
cats, HR transiently increased but no changes were recorded in MAP (Honkavaara et al., 2017b). 
Likewise, no changes were detected in MAP, PaO2, or PaCO2, while HR and RR increased 
significantly from the baseline for up to 30 minutes following IV vatinoxan (200 μg/kg) in horses (de 
Vries et al., 2016). Furthermore, in cats, 300 μg/kg IV did not induce any relevant changes in HR 
(Honkavaara et al., 2017a).  




2.4.2.2 Sedative effects  
In horses, vatinoxan (200 μg/kg IV) did not induce any significant changes in sedation scores (de 
Vries et al., 2016). Similarly in cats, vatinoxan (IV and IM) caused no significant change in sedation 
scores from baseline values (Honkavaara et al., 2017a, b). Recently, vatinoxan was found to increase 
the minimum alveolar concentration (MAC) of sevoflurane in dogs (Hector et al., 2017) and 
isoflurane in cats (Pypendop et al., 2019). The underlying mechanism of this effect remains unclear; 
however because the MAC-reducing effect of α2-adrenoceptor agonists is exerted at the supraspinal 
level within the CNS (Kita et al. 2000), the authors speculated that vatinoxan may not be void of all 
central effects (Pypendop et al., 2019). 
2.4.2.3 Other effects 
A high dose of vatinoxan (30 mg/kg) induced hypoglycemia after intraperitoneal injection in mice 
(Durcan et al., 1991). In contrast, IV vatinoxan infusion up to 8 mg produced no consistent changes 
in blood glucose, insulin or plasma catecholamine concentrations in healthy human volunteers 
(Schafers et al., 1992). Similarly, there was no effect on fasting plasma glucose and insulin 
concentrations in human volunteers receiving two different doses of vatinoxan (15 and 30 mg) orally 
(Warren et al., 1991). In horses, vatinoxan (200 μg/kg IV) has no significant effect on plasma glucose 
concentrations (Pakkanen et al., 2018).  
In horses, vatinoxan (200 μg/kg IV) did not cause detectable changes in intestinal motility, but three 
out of seven horses showed signs of restlessness and mild colic (kicking their pelvic limbs towards 
the abdomen). Two of these horses were reported to pass watery feces (de Vries et al., 2016). In dogs, 
one minute after IV vatinoxan (250 μg/kg), two out of eight dogs started to salivate, which lasted for 
a few minutes (Honkavaara et al., 2011).      
2.4.2.4 Pharmacokinetic properties  
There are no previous studies describing the pharmacokinetics of vatinoxan in sheep or other 
ruminant species. However, there exists a limited number of studies in other species. In dogs, the 
disposition data for IV vatinoxan (250 μg/kg) were: VZ was 0.41 ± 0.13 L/kg, CL was 7.8 ± 3.4 
mL/kg/min, and the AUC0-60 was 26,600 ± 9100 ng/min/mL (Honkavaara et al., 2012). In cats, the 
following pharmacokinetic data after IV administration of vatinoxan (300 μg/kg) were reported: T½, 
median (range), 122 (99–139) minutes, Vss was 491 (379–604) mL/kg, CL was 3 (2–4.5) mL/min/kg, 
and the AUC was 100,665 (66,124–152,045) ng.min/mL (Pypendop et al., 2016). Similar results were 
obtained after a higher dose (600 μg/kg IV) with Vdss was 558 (501–605) mL/kg, T½ was 97 (69–105) 
minutes, CL was 4.5 (3.8–6.3) mL/min/kg, and AUC was 133,466 (95,084–158,349) ng/min/mL 
(Pypendop et al., 2017b). It is worth mentioning that in the dog study (Honkavaara et al., 2012), the 
samples were collected only for 60 minutes after vatinoxan administration, which in part might 
explain the differences in pharmacokinetic variables from those reported for cats. On the other hand, 
following IM administration (600 μg/kg) of vatinoxan, the Cmax was 913.9 (614–1436) ng/mL, Tmax 
was 9.5 (1.3–19.4) minutes, the AUC was 102,450 (70,819–216,308) ng.min/mL, T½ was 76.8 (64.2–
98.8), and the bioavailability was 99.5% (52.6–148.7) in cats (Pypendop et al., 2017b). In horses 
treated with IV vatinoxan (200 μg/kg), the VZ was 1189 ± 121 mL/kg, T½ was 141 ± 28.6 minutes, 
CL was 6 ± 0.99 mL/min/kg, and the AUCinf was 34,157 ± 5652 ng.min/mL (de Vires et al., 2016). 




Overall, based on available studies, vatinoxan thus appears to have a lower volume of distribution 
and a slower clearance when compared to all clinically relevant α2-adrenoreceptor agonists.                                  
2.4.2.5 The use of vatinoxan with 2-adrenoceptor agonists 
In recent years, the effects of vatinoxan on the cardiopulmonary, sedative, and pharmacokinetic 
properties of various α2-adrenoreceptor agonists have been described for several species (Table 1). 
However, in sheep only two previously published studies were located. Bryant et al. (1998) 
investigated the impact of vatinoxan (264 μg/kg IV) on medetomidine-induced cardiovascular 
changes in sheep and horses. Vatinoxan was proceeded and followed by methoxamine (75 μg/kg IV) 
and medetomidine (5 μg/kg IV) was given after cardiovascular variables (HR and MAP) returned to 
baseline levels or remained stable. The authors reported that vatinoxan attenuated the reduction in 
HR and the elevation in MAP caused by medetomidine (Bryant et al., 1998). Likewise, vatinoxan 
(250 μg/kg) alleviated all hemodynamic changes induced by dexmedetomidine (5 μg/kg) in sheep 
after IV co-administration (Raekallio et al., 2010). In addition, vatinoxan had no relevant effects on 
the degree of induced sedation in sheep (Raekallio et al., 2010). Similar findings were reported in 
other species with various agonists, such as in dogs (Honkavaara et al., 2008; Restitutti et al., 2011, 
Rolfe et al., 2012; Salla et al., 2014a), horses (de Vries et al., 2016; Tapio et al., 2018), cats (Pypendop 
et al., 2016; Honkavaara et al., 2017a), rats (Doze et al., 1989), and humans (Warren et al., 1991). 
Nevertheless, vatinoxan significantly reduced the total duration of sedation (Restitutti et al., 2011; 
Vainionpää et al., 2013b; Bennett et al., 2016). In standing horses sedated with medetomidine (7 
μg/kg IV) with and without vatinoxan (140 μg/kg IV) and followed by 3.5 μg/kg/h medetomidine as 
a continuous rate infusion for 60 minutes, vatinoxan decreased the mean sedation scores during the 
first 20 minutes (Tapio et al., 2019). In contrast, vatinoxan significantly intensified the initial sedative 
effects of medetomidine, as reported in dogs (Restitutti et al., 2017; Kallio-Kujala et al., 2018a, b) 
and in cats with dexmedetomidine (Honkavaara et al., 2017b) following concurrent IM administration 
in the same syringe, which presumably was a consequence of the accelerated absorption as discussed 
earlier.  
To the best of our knowledge, no previous studies have investigated IM co-administration of 
vatinoxan and medetomidine in sheep. Similarly, the effects of vatinoxan when combined with 
medetomidine and ketamine remain unexplored in this species. Furthermore, the interactions between 
vatinoxan and atipamezole have not been studied previously in sheep sedated with an α2-
adrenoreceptor agonists, with or without ketamine. Therefore, the following aims were defined for 
the present dissertation:  








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































       






















































































































































































































































































































































































































































   





























































































































































































































































































































































































































































































































































































































       















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































      




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3 AIMS OF THE STUDY 
1. To investigate the cardiopulmonary effects of vatinoxan in conscious sheep treated with 
medetomidine or medetomidine-ketamine, with special reference to concomitant IM administration 
and interactions with atipamezole (studies I and II). 
2. To determine the effect of vatinoxan on the exposure to medetomidine following IM co-
administration (studies I–III).  
3. To explore the impact of vatinoxan on plasma concentrations of atipamezole (studies I–III), 
ketamine and norketamine (study I), and dexmedetomidine (study IV). 
4. To evaluate the impact of vatinoxan on medetomidine-ketamine and medetomidine-induced 
sedation and reversal with atipamezole (studies I–III). 
5. To characterize the influence of vatinoxan on dexmedetomidine-induced pulmonary and 
cardiovascular changes in sevoflurane-anesthetized sheep (study IV). 
  




4 MATERIALS AND METHODS 
4.1 Animals 
Nine adult female sheep (4 Texel and 5 Crossbred [Texel, Dorset, and Gotland] sheep), aged between 
1 and 5 years during the experiments, were used in these studies. For study I all nine sheep were 
included, whereas for studies II and III eight of them, and for study IV seven animals were used. 
Approximately one month before the beginning of study I, the right carotid arteries were surgically 
exteriorized into a subcutaneous position under general anesthesia using the surgical method 
described previously for standing horses (Tapio et al., 2017). The animals were premedicated with 
IV detomidine (50 μg/kg), butorphanol (0.5 mg/kg), and ketamine (0.5–1 mg/kg), anesthesia was then 
induced with IV propofol until effect and maintained with isoflurane. All studies were approved by 
the National Experiment Board of Finland (License number: ESAVI/9394/04.10.07/2015). The sheep 
were housed as a single group with free access to hay and water. Only before general anesthesia 
(study IV) was hay, but not water, withdrawn for 24 hours. The animals were considered healthy 
based on clinical examination, complete blood counts and serum chemistry analyses. 
4.2 Instrumentation  
In studies I and II the animals were maintained upright in a padded sling. A single-lumen polyethane 
central venous catheter (Cavafix Certo, B. Braun, Melsungen, Germany, 18 G; study I and 14 G; 
study II) was inserted via the left jugular vein into the thoracic vena cava for measuring the central 
venous pressure (CVP) and collecting blood samples (study II). An 18-gauge venous cannula 
(Terumo Europe, Leuven, Belgium) was then placed in the right jugular vein for lithium injection and 
a 20-gauge arterial catheter (Becton Dickinson, UT, USA) was inserted into the elevated carotid 
artery. The catheters were later connected to pressure transducers (Gabarith PMSET, Becton 
Dickinson, UT, USA). Local anesthesia (0.5 mL of Lidocaine 20 mg/mL; Orion, Turku, Finland) was 
subcutaneously injected at each site prior to insertion of the catheters.  
For study IV, the cephalic vein was cannulated (18 G) and anesthesia was induced with IV 
administration of propofol to effect. Following orotracheal intubation, anesthesia was maintained 
with sevoflurane (SevoFlo, Abbott Laboratories, IL, USA) in 50% inspired oxygen (Perseus A 500, 
Dräger, Germany). A triple-lumen Swan-Ganz catheter (7 Fr, 110 cm, Edwards Lifesciences, CA, 
USA) was introduced via a 10 G 3 Teflon introducer (Becton Dickinson, UT, USA) via the left jugular 
vein and the tip was advanced under pressure guidance into the pulmonary artery. The carotid artery 
was catheterized similar to studies I and II and a 16 G cannula was placed in the right jugular vein 
for drug administration. All catheter placements were performed aseptically. Study III was conducted 
without any instrumentation. 
4.3 Study design 
All studies were crossover designs with randomly allocated treatments using balanced Latin square 
design. The washout period between treatments was at least 14-days (studies I–III), and 20-days for 
study IV. A summary of studies, treatments, and doses is presented in Table 2. The investigators 
assessing sedation (studies I–III), monitoring cardiovascular data (studies I–IV), and evaluating the 
CT-scans (study IV) were masked to the treatments.  




4.4 Drugs and doses 
Medetomidine (Dorbene 1 mg/mL, Syva Laboratories S.A., Spain), dexmedetomidine (Dexdomitor 
0.1 mg/mL, Orion Pharma, Turku, Finland), vatinoxan (Vetcare Ltd., Mäntsälä, Finland), ketamine 
hydrochloride (Ketador vet. 100 mg/mL, Richter Pharma AG, Wels, Austria), and atipamezole 
(Alzane 5 mg/mL, Syva Laboratories) were used. Vatinoxan was provided in powder form. Prior to 
each treatment, it was dissolved in medetomidine (studies II and III), medetomidine and ketamine, 
and isotonic saline (study I), or isotonic saline only (study IV). Medetomidine and/or medetomidine-
ketamine, with or without vatinoxan and/or isotonic saline, were injected IM in the same syringe 
(studies I–III), atipamezole (ATI) was administered IM in the contralateral muscle 60 (study I) or 30 
(studies II and III) minutes after the initial treatment. In study IV, vatinoxan was given as an IV bolus 
ten minutes (T-10) before dexmedetomidine, which was diluted in isotonic saline to a final volume 
of 20 mL and administered IV over 30 seconds via the jugular vein (Table 2). 





a. MED 30 μg/kg + KET 1 mg/kg IM (Med-Ket) 
b. Med-Ket + 150 μg/kg VAT IM (Med-Ket-Vat150) 
c. Med-Ket + 300 μg/kg VAT IM (Med-Ket-Vat300) 
d. Med-Ket + 600 μg/kg VAT IM (Med-Ket-Vat600) 







a. Medetomidine 30 μg/kg IM (MED) 
b. MED + 300 μg/kg VAT IM (Med-Vat) 
c. MED followed by ATI at T30 (150 μg/kg, IM) 
d. Med-Vat followed by ATI at T30 (150 μg/kg, IM)  
III 
a. Medetomidine 30 μg/kg IM (MED) 
b. MED + 300 μg/kg VAT IM (MED+VAT) 
ATI (150 μg/kg, IM) 30 minutes later to all treatments 
Clinical sedation 
Atipamezole reversal 
IV 7 a. Dexmedetomidine 3 μg/kg IV (DEX) 
b. DEX preceded by VAT 150 μg/kg IV (VAT+DEX) 
Cardiopulmonary   
CT imaging, BAL 
Ventilatory mechanics 
4.5 Cardiopulmonary monitoring 
A continuous lead II electrocardiogram, invasive arterial and central venous pressures (studies I, II, 
and IV) and pulmonary arterial pressures (study IV) were recorded (S/5 Compact Critical Care 
Monitor, Datex-Ohmeda, Helsinki, Finland). The invasive pressure transducers were tested against a 
mercury manometer and zeroed to atmospheric pressure prior to baseline measurements. The height 
at the shoulder joint was used as the zero reference point for standing blood pressure measurements 
(studies I and II), and the level of the CT-table for sternal recumbency (study IV). Samples for arterial 
blood gas analysis were taken via the carotid arterial catheter into pre-heparinized syringes, stored in 
iced water and analyzed immediately (studies I, II, and IV). In study II, central venous blood samples 




were similarly collected from the CVP catheter for blood gas analysis, whereas in study IV mixed 
venous blood samples were collected from the distal port of the pulmonary arterial catheter. The 
arterial hemoglobin content, pH, PaO2, PaCO2, glucose, electrolyte and lactate concentrations were 
measured and bicarbonate (HCO3-) calculated using the following blood gas analyzers: Epoc (Epocal 
Inc, Ottawa, ON, Canada; study I), GEM 4000 (GEM Premier 4000, Bedford, MA, USA; study II), 
and ABL 855 (Radiometer, Copenhagen, Denmark; study IV). In study I, Hb contents were analyzed 
using a hematology system (ADVIA 2120i, Siemens Healthcare GmBH Germany). Respiratory rates 
(RR) were calculated by observing chest wall movements (studies I and II). In study III, pulse rates 
were counted by palpating the carotid pulse wave, whereas in study IV, tidal volume (VT), end-tidal 
carbon dioxide (ETCO2), respiratory rate (fR), fraction of inspired oxygen (FiO2), end-tidal 
sevoflurane, total dynamic compliance (Cdyn), and peak inspiratory pressure (PIP) were obtained from 
the anesthesia monitor (Perseus A 500, Dräger, Germany). 
Cardiac output was measured using the lithium dilution method (LidCO Plus Hemodynamic Monitor, 
LidCO Ltd., Cambridge, UK), as previously described in dogs (Mason et al., 2001) and sheep 
(Raekallio et al., 2010). Briefly, the lithium sensor was prepared as described in the operation manual 
and attached to the side port of a 3-way stopcock connected to the arterial catheter. To begin the 
cardiac output measurements, the flow regulator was activated at a rate of 4 mL/min and a standard 
dose of 0.075 mmoL lithium chloride (previously placed into an extension set) was flushed with 20 
mL of saline via the jugular cannula. The LidCO computer requires blood hemoglobin and sodium 
concentrations to produce accurate CO values, and standard concentrations of 10 g/dL and 140 
mmol/L were initially used for hemoglobin and sodium, respectively. Later, they were corrected with 
measured values obtained from simultaneously taken arterial blood samples using a formula provided 
by LidCO Ltd.  
Standard formulae were used for calculation of cardiopulmonary indices (Boyd et al., 1991, Haskins 
et al., 2005). A formula specific to sheep (Maginniss et al., 1986) was used for calculating arterial 
(SaO2; studies I and II) and venous oxygen saturation (SvO2; study II). In study IV, SpO2 was obtained 
directly from the pulse oximeter (Nonin PalmSAT 2500 series, MN, USA).  
4.6 Assessment of sedation 
The sedation was subjectively assessed using a visual analogue sedation score (VAS) with 0 
indicating no sedation and 10 deep sedation (studies I–III). Additionally, in study III a descriptive 
sedation scale (Kästner et al., 2003) was used, with 0 indicating standing, alert and normal behavior 
while 10 indicated lateral recumbency with no movement. The sedation was evaluated before giving 
the initial medetomidine-containing treatments and at intervals thereafter for two hours (studies I and 
II) and up to 5 hours (study III). Moreover, in study III, the time (minutes) elapsed from drug injection 
until first signs of sedation, the time to deep sedation (recumbent and unable to support the head), and 
the time from atipamezole administration until recovery (standing-up) were recorded. The area under 
the time-sedation curves (AUC) were calculated using the trapezoidal method from baseline to 70 
minutes (study I) and from baseline to 30 minutes (study III) for each sheep. Resedation was assessed 
subjectively by observing signs of reduced alertness and activity after the initial recovery.    




4.7 Drug concentrations in plasma  
Blood samples were collected into EDTA tubes from the carotid artery catheter in studies I, II and 
IV, whereas in study III they were obtained from the jugular veins by direct venipuncture. Samples 
were placed in iced water, centrifuged at 3000 x g for 15 minutes and the plasma was stored at -20 
°C until analyzed. A summary of the drugs analyzed in each study is presented in Table 3. All analyses 
were performed with liquid chromatography mass spectrometry (LC-MS/MS).  
Table 3. Summary of individual drug analyses. 
Study Analyzed drugs 
I Dexmedetomidine, levomedetomidine, ketamine, norketamine, vatinoxan & atipamezole  
II 
Dexmedetomidine, levomedetomidine, vatinoxan & atipamezole 
III 
IV Dexmedetomidine & vatinoxan  
 
The concentrations of dex- and levomedetomidine (reference standard: racemic medetomidine, TRC, 
Toronto, Ontario, Canada) in EDTA plasma were calculated after solid-phase extraction (Sep-
Pak®tC18 96 well extraction plates, Waters Corporation, Milford, MA, USA) with racemic d3-
medetomidine as the internal standard. After chiral separation (Chiralpak® AGP column, 4 x 150 
mm, 5 μm, Chiral Technologies Europe, Illkirch, France) with 10 mM ammonium acetate (pH 4.5) 
and acetonitrile containing 0.1 % formic acid as solvents, quantitative detection was performed in 
multi-reaction monitoring mode (MRM) with a triple quadrupole mass spectrometer (triple 
quadrupole mass spectrometer, 4000QTrap, MDS Sciex, Concord, Ontario, Canada). The 
chromatograms were processed with industry-standard software (Applied Biosystems/MDS Sciex 
software, Analyst version 1.6.1). The linear concentration range was from 0.10 to 10.0 ng/mL. The 
inter-assay accuracy of the quality control samples (at 0.225, 1.0, 8.0 and 50 ng/mL) ranged from 
94.4 to 99.8 % (dexmedetomidine) and 92.5 to 99.2 % (levomedetomidine).  
For ketamine, norketamine, vatinoxan and atipamezole, 50 μL plasma aliquots were treated with in-
well protein precipitation on a Sirocco plate (Sirocco plate, Waters Co., Milford, MA, USA) with 250 
μL of internal standard solution in acetonitrile (containing 100 ng/mL propranolol and 20 ng/mL 
chlorpromazine). After vigorous mixing for 5 min, the samples were centrifuged for 20 min at 4000 
RPM. 50 μL aliquots of the sample supernatants were transferred on to UPLC 96-well plates, diluted 
with 450 μL of 20 % acetonitrile in water and analyzed. Reference samples were prepared in drug-
free sheep plasma at analyte concentrations of 0.02 to 20 000 ng/mL. Quality control samples were 
analyzed at concentrations of 0.2, 2, 20, 200 and 2000 ng/mL. The detection limit was 1 ng/mL for 
vatinoxan, ketamine, and atipamezole and 0.5 ng/mL for norketamine. The quantitation range for 
vatinoxan was 1–10,000 ng/mL (studies I–III) and 2–2000 ng/mL (study IV), while for ketamine and 
norketamine they were 1–10,000 and 0.5–2000 ng/mL, respectively, and 1–10,000 ng/mL for 
atipamezole. The accuracy (%) for vatinoxan, ketamine, norketamine, and atipamezole were 96–105, 
92–106, 93–103, and 91–108, and the precision (%) were 6.8–13, 1.3–19.5, 0.5–19.9, and 0.4–11.3, 
respectively.  
The pharmacokinetic variables in study I for AUC0–50 were calculated using the trapezoidal method, 
while Cmax and Tmax values were derived from the plasma concentration data. 




4.8 Computed tomography (CT) 
In study IV, CT was performed (GE Lightspeed VCT 64, GE Healthcare, Waukesha, WI, USA). The 
lung parenchyma caudal to the level of heart was scanned at 140 kV, at an mA noise index of 18.0 
(min 120 mA/max 710 mA), and slice thickness of 0.625 mm, with a rotation time of 0.4 sec and 
detector pitch at 0.984. The CT scanner was calibrated daily according to the hospital’s protocol. The 
cross-sectional areas (cm2) of the caudal pulmonary artery and vein were measured in the right lung 
field. Two regions of interest (ROI) of 0.5 cm2 were drawn on this same image as described previously 
(Kästner et al., 2007): one positioned dorsally close to the periphery of the lung parenchyma, and the 
other ventrolaterally to the main bronchus (Figure 4A), and the CT values of each ROI were 
calculated as Hounsfield units (HU). The measurements for each ROI were conducted in triplicate by 
an investigator masked to the treatments, for a total of three times with at least a one week interval.  
4.9 Bronchoscopy and bronchoalveolar lavage (BAL) 
In study IV, bronchoscopy and bronchoscopy-guided BAL were performed via the endotracheal tube 
approximately five minutes after the last CT scan. Fifty milliliters of saline was infused through the 
work channel of the bronchoscope (Olympus GIF N180, Olympus Europa GmbH, Japan) into the 
right dorsal and right accessory lung lobes, and the fluid was immediately withdrawn and placed on 
ice. The BAL fluid was then filtered through a sterile gauze, after which the quantity of white blood 
cells was calculated and differential counts were performed from cytocentrifuge smears stained with 
May-Grünwald Giemsa.   
4.10 Statistical analyses 
The cardiopulmonary variables were compared within and between treatments with a mixed model 
repeated measures ANCOVA, followed by post-hoc tests where appropriate. Treatment comparisons 
for changes from baseline by time and changes within treatment were computed from the same model 
with contrast (study I) and Holm–Bonferroni post-hoc corrections were used where applicable 
(studies II–IV). Pharmacokinetic variables and plasma drug concentrations between treatments and/or 
studies at certain time-points were analyzed with one-way ANOVA followed by the Tukey post hoc 
test and Student’s t-test as appropriate (studies I and II). In study I, the trapezoidal method was used 
to calculate the areas under the time-sedation score curves from baseline to 70 minutes for each sheep 
and the values were analyzed with a repeated-measures ANOVA. Equivalence among treatments was 
to be accepted when the 95% confidence interval of the geometric mean ratio was within the reference 
limits (0.8 and 1.25). In studies II and III, the sedation scores were analyzed with Friedman’s test for 
the time effect within each treatment while comparisons between treatments were analyzed with 
Kruskal–Wallis and Mann–Whitney U tests where applicable. The CT measurements and BAL fluid 
differential white blood cell counts were analyzed with the Wilcoxon Signed-Rank test. For all 
studies, P < 0.05 was considered statistically significant. The analyses were computed using IBM 
SPSS Statistics version 24.0 for Windows (IBM Corp., Armonk, NY, USA) and SAS for Windows, 







5.1 Cardiopulmonary effects  
The data for cardiopulmonary variables from all studies are summarized in Tables 4–6 and Figures 
1–3. In study I, addition of vatinoxan prevented the initial medetomidine-induced increase in SAP, 
DAP, MAP, and CVP, and subsequent blood pressures were also significantly below baseline values 
after all doses of vatinoxan (Table 4). Without vatinoxan, HR remained significantly below baseline 
until reversal with atipamezole (Figure 1). Similarly, in study II, HR decreased after MED and, even 
after atipamezole, remained below the baseline values (Figure 2). Cardiac output decreased after 
MED alone and remained below baseline throughout the observational period. Atipamezole reversed 
this medetomidine-induced decrease (Table 4 and 5). Systemic vascular resistance increased after 
MED alone and remained significantly elevated even after atipamezole. In contrast, no significant 
hemodynamic changes were detected with Med-Vat regardless of atipamezole (Figures 1 and 2). In 
study IV, except for MAP and SVR, both of which significantly decreased from baseline, 
hemodynamic variables did not significantly change from pre-treatment values regardless of the 
presence of vatinoxan (Table 6). Oxygen delivery decreased significantly after all treatments and 
remained below the pre-treatment level until atipamezole (study I). Similarly, arterial oxygen content 
(CaO2) decreased from baseline, but was significantly higher with medetomidine-ketamine than 
treatments that included vatinoxan (study I). In study II, the changes in DO2, and CaO2 were 
comparable with those in study I, where atipamezole significantly increased both values.        
Initially, PaO2 decreased significantly after all treatments in studies I and II (Tables 4 and 5). In study 
IV, pre-administration of vatinoxan prevented the increase in alveolar to arterial difference in partial 
pressure of oxygen (P(A-a)O2) and the decreases in PaO2, PvO2, and PaO2/FiO2 ratio (Table 6). 
Moreover, vatinoxan prevented both the decrease in Cdyn and the need to increase PIP (Figure 3). On 
CT imaging, lung density was significantly increased after dexmedetomidine alone, while pre-
treatment with vatinoxan prevented those changes (Figure 4). For the bronchoscopy, no excessive 
mucus or edema were detected within the bronchi after either treatment. Additionally, no visual 
abnormalities were observed in BAL fluid and there were no significant differences in differential 
white blood cell counts between treatments.    
5.2 Plasma concentrations of drugs 
Dexmedetomidine, levomedetomidine, and vatinoxan concentrations in plasma from studies I and II 
are presented in Figures 5 and 6. The concentrations of the enantiomers did not differ from each other 
in any of the studies. Additionally, in study I, no significant differences in their concentrations in 
plasma were detected between treatments (Figure 5). Conversely, in study II, the dexmedetomidine 
and levomedetomidine concentrations were approximately three times higher with the inclusion of 
vatinoxan at 20 minutes (Figure 6). Likewise, concentrations of both enantiomers were approximately 
doubled at 30 minutes with the addition of vatinoxan (study III). After atipamezole, the concentrations 
of dexmedetomidine and levomedetomidine in plasma were significantly higher when medetomidine 
was administered alone (Figures 5 and 6). Pre-administered intravenous vatinoxan did not affect the 
exposure to dexmedetomidine in sevoflurane-anesthetized sheep (study IV). Vatinoxan 





changes were detected in atipamezole concentrations between treatments, regardless of the presence 
or absence of either vatinoxan or ketamine. For example, 30 minutes after reversal (T90, study I; T60, 
study II) the concentrations of atipamezole were (range) 31.7–36.4 ng/mL (study I) and 34.7–35.6 
ng/mL (study II). Similarly, the concentrations of ketamine and norketamine did not significantly 
differ between treatments (study I; Figure 8).         
5.3 Sedative effects 
In study I, sedation scores did not significantly differ between treatments before or after reversal with 
atipamezole (Table 7). Areas under the time-sedation curves (AUCsed0–70) were [median (range)] 540 
(449–578), 473 (374–529), 482 (406–795), and 497 (426–637) for Med-Ket, Med-Ket-Vat150, Med-
Ket-Vat300, and Med-Ket-Vat600; respectively. Addition of vatinoxan significantly intensified the 
initial sedative effect of medetomidine (studies II and III). After reversal, the scores were significantly 
lower with treatments that included vatinoxan when compared to medetomidine alone (Table 8, 
Figure 9). In study I, immediately after atipamezole administration, some animals exhibited signs of 
agitation accompanied with tremor of the fascial muscles. No such signs were observed in studies II 
and III.       
5.4  Rectal temperature 
Rectal temperatures declined significantly from 30 minutes onwards after all treatments in study I, 
including the period after atipamezole, but no clinically relevant hypothermia (i.e. temperature < 36 
°C) was observed (Table 4). In study II, a significant decrease was recorded after 40 minutes, but 
only for treatments that did not include atipamezole (Table 5). No changes in rectal temperature were 
detected in study IV (Table 6).  
5.5  Hemoglobin content 
In general, the Hb concentration decreased after all treatments, although the decline was more 
pronounced after treatments that included vatinoxan. Reversal with atipamezole restored the Hb 
values (studies I and II; Tables 4 and 5).  
5.6 Plasma glucose 
Medetomidine significantly increased plasma glucose concentrations, which remained elevated even 
after atipamezole. Both concurrent (studies I and II) and pre-administration of vatinoxan (study IV), 





Table 4. Mean ± SD of CO, SAP, DAP, PaO2, PaCO2, Hb, glucose, DO2, SaO2, CaO2, and rectal 
temperature (Temp.) from study I (Adam et al., 2018a) in nine sheep sedated with medetomidine-
ketamine with and without vatinoxan and administered atipamezole 60 minutes later to reverse 
sedation (See Table 2 for treatments key). *Statistically significantly different (P < 0.05) from 
baseline within the same treatment (row).  †Significant difference (P < 0.05) from Med-Ket within 
the same column. 
  Time after administration (min) 
Variable Treatment Baseline 15 30 45 90 
CO 
(L/min) 
Med-Ket 4.2 ± 0.54 3.4 ± 1.26* 3.6 ± 0.54 3.8 ± 0.96 4.5 ± 0.81 
Med-Ket-Vat150 4.7 ± 0.67 3.9 ± 0.70* 4.6 ± 0.87 4.6 ± 1.13 5.2 ± 1.77 
Med-Ket-Vat300 4.9 ± 0.90 4.6 ± 1.59 4.2 ± 0.56 4.1 ± 0.57 4.9 ± 1.28 
Med-Ket-Vat600 4.9 ± 1.51 4.1 ± 1.09* 4.0 ± 1.30* 3.7 ± 0.93* 5.8 ± 2.51 
SAP 
(mmHg) 
Med-Ket 120 ± 8 136 ± 10* 132 ± 8* 124 ± 19† 130 ± 17 
Med-Ket-Vat150 125 ± 15 127 ± 13† 114 ± 11† 99 ± 7*† 129 ± 12 
Med-Ket-Vat300 123 ± 11 122 ± 9† 102 ± 15*† 91 ± 14*† 133 ± 8* 
Med-Ket-Vat600 123 ± 14 109 ± 17*† 89 ± 12*† 84 ± 9*† 131 ± 7 
DAP 
(mmHg) 
Med-Ket 91 ± 4 103 ± 10* 102 ± 12* 97 ± 16 95 ± 7 
Med-Ket-Vat150 95 ± 11 98 ± 7 88 ± 9† 77 ± 8*† 94 ± 13 
Med-Ket-Vat300 93 ± 10 94 ± 6† 78 ± 9*† 68 ± 13*† 98 ± 9 
Med-Ket-Vat600 92 ± 9 85 ± 13† 68 ± 13*† 64 ± 11*† 99 ± 7* 
PaO2 
(mmHg) 
Med-Ket 98.1 ± 7.8 71.1 ± 12.4* 68.6 ± 9.3* 73.7 ± 10.0* 99.5 ± 12.7 
Med-Ket-Vat150 99.0 ± 7.7 76.3 ± 13.7* 81.9 ± 11.3*† 86.2 ± 8.6*† 103.0 ± 6.3 
Med-Ket-Vat300 103.3 ± 6.6 79.2 ± 11.8*† 83.1 ± 7.9*† 92.9 ± 8.0*† 97.3 ± 9.4 
Med-Ket-Vat600 94.7 ± 5.7 79.7 ± 11.3*† 81.7 ± 8.2*† 89.6 ± 10.9† 92.8 ± 7.8 
PaCO2 
(mmHg) 
Med-Ket 39.5 ± 4.6 49.5 ± 8.6* 51.5 ± 6.2* 49.4 ± 6.9* 41.0 ± 7.9 
Med-Ket-Vat150 40.2 ± 2.3 52.2 ± 7.6* 51.9 ± 4.9* 50.0 ± 4.4* 43.2 ± 3.7 
Med-Ket-Vat300 39.8 ± 3.3 48.9 ± 7.3* 51.4 ± 7.3* 46.8 ± 3.4* 42.4 ± 2.2 
Med-Ket-Vat600 39.6 ± 2.8 50.8 ± 5.2* 51.2 ± 4.0* 45.7 ± 6.2* 41.3 ± 6.4 
Glucose 
(mmol/L) 
Med-Ket 4.6 ± 1.5 5.8 ± 1.5* 6.7 ± 1.8* 7.8 ± 1.9* 8.6 ± 2.5* 
Med-Ket-Vat150 4.3 ± 0.5 4.5 ± 0.5† 4.7 ± 0.9† 4.7 ± 0.9† 5.0 ± 0.8*† 
Med-Ket-Vat300 4.9 ± 1.8 5.0 ± 1.9† 4.9 ± 2.0† 4.9 ± 1.9† 5.1 ± 1.9† 
Med-Ket-Vat600 4.3 ± 0.3 4.3 ± 0.6† 4.2 ± 0.6† 4.1 ± 0.5† 4.1 ± 0.5† 
Hb (g/dL) 
 
Med-Ket 9.4 ± 0.8 8.88 ± 0.86* 8.53 ± 0.59* 8.58 ± 0.95* 9.58 ± 1.12 
Med-Ket-Vat150 9.3± 0.97 8.1 ± 0.78*† 7.7 ± 0.60*† 7.5 ± 0.60*† 9.2 ± 0.93 
Med-Ket-Vat300 9.1 ± 0.61 8.2 ± 0.83*† 7.7 ± 0.63*† 7.5 ± 0.64*† 9.2 ± 0.93 
Med-Ket-Vat600 9.4 ± 1.05 8.3 ± 0.77*† 7.7 ± 0.67*† 7.5 ± 0.63*† 8.9 ± 0.81 
SaO2  
(%) 
Med-Ket 95.4 ± 0.9 87.4 ± 6.3* 86.8 ± 5.1* 89.1 ± 4.1* 95.3 ± 1.8 
Med-Ket-Vat150 95.5 ± 1.0 89.6 ± 5.6* 91.8 ± 3.2*† 93.2 ± 1.7† 96.0 ± 0.6 
Med-Ket-Vat300 96.0 ± 0.7 90.9 ± 3.4* 92.4 ± 2.2*† 94.5 ± 1.2† 95.0 ± 1.7 
Med-Ket-Vat600 94.9 ± 0.8 91.1 ± 3.6*† 92.0 ± 2.2*† 93.7 ± 2.2† 94.5 ± 1.4 
DO2 
(mL/kg/min) 
Med-Ket 12.2 ± 2.1 8.9 ± 2.2* 9.3 ± 1.4* 8.7 ± 1.3* 13.9 ± 3.4 
Med-Ket-Vat150 12.9 ± 1.6 8.5 ± 1.0* 10.2 ± 2.1* 10.1 ± 2.4* 14.0 ± 3.0 
Med-Ket-Vat300 14.2 ± 3.4 10.9 ± 3.6* 9.9 ± 2.3* 9.6 ± 1.8* 14.0 ± 3.8 
Med-Ket-Vat600 14.4 ± 6.9 9.9 ± 2.9* 9.3 ± 3.1* 8.2 ± 2.0* 15.0 ± 3.0 
CaO2 
(mL/dL) 
Med-Ket 128.5 ± 10.6 114.3 ± 13.0* 106.5 ± 7.1* 111.1 ± 10.9* 130.9 ± 16.1 
Med-Ket-Vat150 127.7 ± 12.1 105.3 ± 9.9*† 102.2 ± 6.2*† 101.3 ± 7.3*† 127.3 ± 16.9 
Med-Ket-Vat300 126.2 ± 8.4 108.1 ± 12.3* 103.2 ± 8.2* 102.8 ± 8.7*† 123.5 ± 13.5 
Med-Ket-Vat600 128.0 ± 13.6 109.1 ± 9.6* 101.5 ± 7.9*† 100.5 ± 8.2*† 117.5 ± 9.6 
Temp (°C) 
Med-Ket 39.4 ± 0.49 39.3 ± 0.51 38.9 ± 0.58* 38.8 ± 0.68* 38.6 ± 0.86* 
Med-Ket-Vat150 39.3 ± 0.37 39.3 ± 0.25 39.0 ± 0.36 38.7 ± 0.29* 38.7 ± 0.36* 
Med-Ket-Vat300 39.4 ± 0.35 39.2 ± 0.49 39.0 ± 0.52* 38.6 ± 0.53* 38.6 ± 0.72* 







Table 5. Mean ± SD of CO, SAP, DAP, PaO2, PaCO2, Hb, glucose, DO2, SaO2, CaO2, and rectal 
temperature (Temp.) from study II (Adam et al., 2018b) in eight sheep sedated with medetomidine 
with and without vatinoxan and administered atipamezole or saline 30 minutes to reverse sedation 
(See Table 2 for treatments key). *Significant difference from the baseline within the same treatment, 
†Significant difference between MED and Med-Vat, ‡Significant difference between MED+ATI and 
Med-Vat+ATI, §Significant difference between MED and MED+ATI, and #Significant difference 
between Med-Vat and Med-Vat+ATI (P < 0.05). 
  Time after administration (min) 
Variable Treatment Baseline 20 40 60 75 90 
CO 
(L/min) 
MED 4.47 ± 0.81 3.08 ± 0.32 3.32 ± 0.81 3.49 ± 0.69 3.18 ± 0.41 3.14 ± 0.61 
MED+ATI 4.51 ± 0.71 3.31 ± 0.55 3.83 ± 0.85 4.14 ± 1.06 4.27 ± 0.81 4.29 ± 1.09 
Med-Vat 4.68 ± 0.92 3.82 ± 0.60 4.07 ± 0.76 3.55 ± 0.44 3.79 ± 0.77 4.01 ± 1.10 
Med-Vat+ATI 4.29 ± 1.25 4.19 ± 0.67 4.49 ± 1.32 4.90 ± 1.54 4.50 ± 1.55 4.87 ± 1.60 
SAP 
(mmHg) 
MED 126 ± 11 122 ± 9 120 ± 13† 114 ± 12† 110 ± 12 108 ± 13 
MED+ATI 118 ± 8 117 ± 12 130 ± 16 125 ± 11§ 130 ± 19§ 124 ± 10§ 
Med-Vat 121 ± 9 117 ± 9 100 ± 12* 100 ± 9* 103 ± 9* 111 ± 12 
Med-Vat+ATI 118 ± 14 119 ± 11 131 ± 19# 128 ± 13# 126 ± 15# 126 ± 14 
DAP 
(mmHg) 
MED 97 ± 9 95 ± 8 94 ± 8† 91 ± 8† 89 ± 9 88 ± 10 
MED+ATI 91 ± 6 91 ± 8 102 ± 16 96 ± 9 100 ± 17 94 ± 8 
Med-Vat 94 ± 6 92 ± 6 80 ± 8* 77 ± 5* 79 ± 6* 82 ± 6* 
Med-Vat+ATI 91 ± 12 94 ± 7 99 ± 16# 96 ± 11# 96 ± 10# 95 ± 8# 
PaO2 
(mmHg) 
MED 102 ± 7.3 90 ± 5.7* 89 ± 3.5* 89 ± 7.9* 84 ± 5.1* 88 ± 6.1* 
MED+ATI 104 ± 4.5 89 ± 8.4* 90 ± 11.4* 99 ± 12.2 102 ± 9.9§ 102 ± 5.6§ 
Med-Vat 96 ± 10.1 87 ± 14 85 ± 10.6 89 ± 16 92 ± 7.9 91 ± 7.4 
Med-Vat+ATI 101 ± 4.3 90 ± 11.4* 96 ± 9.7 100 ± 6.6 99 ± 8.2 106 ± 9.8# 
PaCO2 
(mmHg) 
MED 38.3 ± 2.9 43.3 ± 4.1 44.7 ± 3.2* 45.4 ± 1.9* 46.7 ± 4.4* 44.9 ± 3.5* 
MED+ATI 38.6 ± 2.6 45.2 ± 3.0* 41.8 ± 2.8* 41.9 ± 2.9§ 41.3 ± 2.6§ 42.1 ± 2.7 
Med-Vat 40.1 ± 2.1 47.0 ± 2.4* 46.0 ± 2.1* 45.4 ± 2.9* 44.7 ± 3.9 45.1 ± 3.4* 
Med-Vat+ATI 39.3 ± 3.1 47.5 ± 2.9* 44.9 ± 8.6 41.0 ± 1.3# 41.5 ± 1.7 40.9 ± 4.2 
Glucose 
(mmol/L) 
MED 3.9 ± 0.4 5.9 ± 1.1*† 7.2 ± 1.5*† 8.2 ± 1.9*† 8.8 ± 2.1*† 9.3 ± 2.4*† 
MED+ATI 3.8 ± 0.4 6.1 ± 0.6*‡ 6.9 ± 1.0*‡ 6.3 ± 1.1*‡§ 6.3 ± 1.1*‡§ 6.1 ± 1.2*§ 
Med-Vat 3.9 ± 0.4 4.4 ± 0.6 4.3 ± 0.7 4.1 ± 0.7 4.2 ± 0.8 4.2 ± 0.8 
Med-Vat+ATI 4.0 ± 0.3 4.6 ± 0.8 4.5 ± 0.9 4.6 ± 0.9 4.6 ± 1.0 4.7 ± 1.1 
Hb (g/dL) 
 
MED 8.79 ± 0.89 7.78 ± 0.92 7.31 ± 0.55* 7.20 ± 0.50* 7.28 ± 0.56* 7.35 ± 0.55*  
MED+ATI 8.26 ± 0.98 7.26 ± 0.58 8.26 ±1.08 8.04 ± 1.00 8.49 ± 1.43 8.66 ± 2.09 
Med-Vat 8.46 ± 0.97 7.56 ± 0.52 7.07 ± 0.52* 6.99 ± 0.56* 6.98 ± 0.47* 7.04 ± 0.45* 
Med-Vat+ATI 8.36 ± 0.65 7.45 ± 0.57 8.34 ± 0.76# 9.27 ± 1.56# 9.34 ± 1.48# 9.09 ± 1.56# 
SaO2  
(%) 
MED 95.8 ± 0.8  94.1 ± 1.2* 93.9 ± 0.6* 93.8 ± 1.6 92.8 ± 1.3* 93.6 ± 1.1* 
MED+ATI 96.1 ± 0.4 93.7 ± 2.0* 93.6 ± 2.4 95.2 ± 1.7 95.7 ± 1.4§  95.9 ± 0.6§ 
Med-Vat 94.9 ± 2.0 92.9 ± 3.1 92.6 ± 3.0 93.0 ± 3.6 94.3 ± 1.7 94.1 ± 1.5 
Med-Vat+ATI 95.8 ± 0.5 93.6 ± 2.4 95.0 ± 1.4 95.6 ± 0.7 95.5 ± 0.8 96.3 ± 0.9# 
DO2 
(mL/kg/min) 
MED 11.1 ± 3.6 6.7 ± 0.8* 6.4 ± 0.5* 6.7 ± 0.7* 6.2 ± 0.8* 6.2 ± 0.9* 
MED+ATI 10.1 ± 1.8 6.5 ± 1.7* 8.7 ± 3.0§ 9.0 ± 3.1 9.9 ± 3.0§ 10.0 ± 2.9§ 
Med-Vat 10.4 ± 1.4 7.8 ± 2.1 7.4 ± 1.5* 6.5 ± 0.9* 7.0 ± 1.3* 7.5 ± 1.9* 
Med-Vat+ATI 9.4 ± 1.0 8.2 ± 1.6 10.5 ± 2.3# 11.4 ± 2.4# 10.9 ± 2.8# 11.7 ± 3.3# 
CaO2 
(mL/L) 
MED 12.0 ± 1.3 10.4 ± 1.2 9.8 ± 0.7* 9.7 ± 0.8* 9.7 ± 0.7* 9.8 ± 0.7* 
MED+ATI 11.4 ± 1.3 9.7 ± 0.7* 10.8 ± 1.6 10.9 ± 1.2§ 11.6 ± 1.8§ 11.9 ± 2.8 
Med-Vat 11.4 ± 1.0 9.9 ± 0.8* 9.3 ± 0.7* 9.3 ± 0.8* 9.4 ± 0.6* 9.5 ± 0.6* 
Med-Vat+ATI 11.5 ± 0.8 10.0 ± 0.7* 11.5 ± 0.9# 12.4 ± 2.1# 12.7 ± 2.0# 12.5 ± 2.1# 
Temp (°C) 
MED 39.3 ± 0.22 39.3 ± 0.17 38.9 ± 0.45 38.7 ± 0.55 38.4 ± 0.60* 38.3 ± 0.75* 
MED+ATI 39.4 ± 0.23 39.4 ± 0.29 39.3 ± 0.47 39.2 ± 0.48 39.1 ± 0.45 39.1 ± 0.37§ 
Med-Vat 39.3 ± 0.24 39.2 ± 0.17 38.7 ± 0.32 38.4 ± 0.47* 38.3 ± 0.52* 38.4 ± 0.57* 






Table 6. Mean ± SD of HR, SAP, DAP, MAP, SPAP, DPAP, MPAP, CVP, CO, SVR, PaO2, PaCO2, 
PvO2, PvCO2, PaO2/FiO2, Hb, glucose, and rectal temperature from study IV (Adam et al., 2018c) in 
seven sevoflurane-anesthetized sheep pretreated with vatinoxan or saline and 10 minutes later 
administered dexmedetomidine (See Table 2 for treatments key). *Significant difference from the 
baseline within the same treatment, †Significant difference between treatments (P < 0.05). 
  Time-points 
Variable Treatment Baseline T-7 T5 T15 T25 
CO (L/min) DEX 
2.87 ± 0.78 3.15 ± 0.72 2.82 ± 0.52 3.05 ± 0.31 3.37 ± 0.25 
VAT+DEX 2.77 ± 0.26 3.63 ± 0.69* 3.25 ± 0.68 3.04 ± 0.41 3.15 ± 0.44 
HR (bpm) DEX 
84 ± 16 84 ± 16 74 ± 9 75 ± 11 76 ± 11 
VAT+DEX 82 ± 8 85 ± 6 76 ± 9 73 ± 8 73 ± 9 
SAP (mmHg) DEX 102 ± 17  105 ± 14 109 ± 9 106 ± 11 92 ± 6 
 VAT+DEX 105 ± 9 101 ± 8 106 ± 6 86 ± 5 80 ± 5 
DAP (mmHg) DEX 84 ± 18 87 ± 13 93 ± 7 89 ± 9 72 ± 7 
 VAT+DEX 85 ± 12 81 ± 8 88 ± 4 66 ± 3 60 ± 422 
MAP (mmHg) DEX 
92 ± 17 95 ± 13 100 ± 8 97 ± 10† 81 ± 6† 
VAT+DEX 94 ± 10 90 ± 8 96 ± 4 75 ± 4* 69 ± 5* 
SPAP (mmHg) DEX 22 ± 3 23 ± 3 25 ± 4 23 ± 4 22 ± 7 
 VAT+DEX 24 ± 4 23 ± 4 23 ± 4 24 ± 6 22 ± 4 
DPAP (mmHg) DEX 15 ± 3 15 ± 4 18 ± 4 17 ± 4 15 ± 6 
 VAT+DEX 17 ± 2 15 ± 1 15 ± 1 16 ± 5 14 ± 2 
MPAP (mmHg) DEX 
18 ± 3 18 ± 3 21 ± 4 20 ± 3 18 ± 5 
VAT+DEX 20 ± 2 19 ± 3 19 ± 2 20 ± 5 17 ± 2 
CVP (mmHg) DEX 
10 ± 3 9 ± 2 13 ± 2 11 ± 2 10 ± 3 
VAT+DEX 13 ± 4 11 ± 3 12 ± 4 11± 3 11 ± 3 
SVR (dynes/sec/cm5) DEX 
2328 ± 440 2279 ± 260† 2547 ± 550 2256 ± 262† 1676 ± 203* 
VAT+DEX 2363 ± 442 1784 ± 306* 2121 ± 396 1678 ± 180* 1480 ± 119* 
PaO2 (mmHg) 
DEX 289 ± 23 280 ± 30 195 ± 85* 213 ± 78* 259 ± 37 
VAT+DEX 280 ± 36 288 ± 23 289 ± 23† 289 ± 19† 291 ± 16† 
PvO2 (mmHg) 
DEX 43 ± 11 42 ± 10 35 ± 7* 37 ± 5* 39 ± 5 
VAT+DEX 41 ± 7 48 ± 9 41 ± 7† 42 ± 7† 42 ± 7 
PaCO2 (mmHg) 
DEX 37 ± 2 37 ± 1 44 ± 8* 43 ± 5* 41 ± 3 
VAT+DEX 36 ± 3 37 ± 1 37 ± 2† 38 ± 2† 37 ± 1 
PvCO2 (mmHg) 
DEX 45 ± 4 45 ± 2 48 ± 5 50 ± 4* 50 ± 3* 
VAT+DEX 43 ± 5 43 ± 2 44 ± 2 45 ± 5† 45 ± 2† 
PaO2/FiO2 DEX 577 ± 46 561 ± 60 392 ± 171* 426 ± 157* 518 ± 74* 
 VAT+DEX 560 ± 72 575 ± 46 578 ± 46† 578 ± 38† 582 ± 32† 
P(A-a)O2 (mmHg)  DEX 31 ± 17 34 ± 30 110 ± 77* 95 ± 74* 51 ± 35 
 VAT+DEX 41 ± 32 27 ± 22 25 ± 22† 25 ± 18† 23 ± 16† 
Hb (g/dL) DEX 
7.7 ± 0.8 7.4 ± 0.8 7.5 ± 0.8 7.6 ± 0.8 7.5 ± 0.8 
VAT+DEX 7.9 ± 0.7 7.8 ± 0.9 7.6 ± 0.8 7.5 ± 0.8 7.3 ± 0.8 
Glucose (mmol/L) DEX 
3.6 ± 0.3 3.5 ± 0.3 3.6 ± 0.3 5.8 ± 1.1 7.0 ± 1.5 
VAT+DEX 4.0 ± 0.5 3.8 ± 0.3 3.7 ± 0.4 3.7 ± 0.3 3.7 ± 0.4 
Temp (°C) DEX 
38.5 ± 0.52 38.3 ± 0.39 38.1 ± 0.31 38.3 ± 0.34 38.3 ± 0.50 










        
        
 Figure 1. Mean ± SD of (a) heart rate (HR), (b) mean arterial pressure (MAP), (c) central venous pressure 
(CVP), and (d) systemic vascular resistance (SVR) in sheep treated with IM medetomidine and ketamine (Med-
Ket [white squares]) with and without three different doses of vatinoxan at 150 μg/kg (Med-Ket-Vat150 [black 
squares]), 300 μg/kg (Med-Ket-Vat300 [triangles]), and 600 μg/kg (Med-Ket-Vat600 [circles]), and received 
IM atipamezole 60 minutes later (arrow). *, †, ‡, §Within a treatment (*Med-ket, † Med-Ket-Vat150, ‡ Med-
Ket-Vat300, and § Med-Ket-Vat600), the value differs significantly (P < 0.05) from the baseline value. ║, ¶, 
# Within a time point, value for a treatment that included vatinoxan (║Med-Ket-Vat300, ¶ Med-Ket-Vat600, 







































































































































































































































Figure 2. Mean ± SD of (a) heart rate (HR), (b) mean arterial pressure (MAP), (c) central venous pressure 
(CVP), (d) and systemic vascular resistance (SVR) in sheep treated with IM medetomidine alone (MED [black 
circles]) or combined with vatinoxan (Med-Vat [white circles]), and received either atipamezole or equal 
volume of saline (MED+ATI, Med-Vat+ATI [black and white squares respectively]) 30 minutes later (arrow). 
*†‡§Significant difference from the baseline within the same treatment (MED, Med-Vat, MED+ATI, and, 
Med-Vat+ATI), ǁsignificant difference between MED and Med-Vat, ¶Significant differences between 
MED+ATI and Med-Vat+ATI, ǀsignificant difference between MED and MED+ATI, and #significant 





















































































































         
 
        
Figure 3. Mean ± SD of (a) tidal volume (VT), (b) peak inspiratory pressure (PIP), (c) dynamic compliance 
(Cdyn), and (d) end-tidal carbon dioxide (ET-CO2) in sevoflurane-anesthetized sheep that were pre-treated with 
vatinoxan (VAT+DEX [black circles]) or saline and 10 minutes later received dexmedetomidine (DEX [white 
circles]). A positive end-expiratory pressure (PEEP) of 5 mmHg was applied throughout the study. †Significant 
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Figure 5. Mean ± SE plasma concentration of (a) dexmedetomidine and (b) levomedetomidine in sheep treated 
with IM medetomidine and ketamine (Med-Ket [white squares]) with and without three different doses of 
vatinoxan (Med-Ket-Vat150, Med-Ket-Vat300 & Med-Ket-Vat600 [black squares, triangles & circles, 
respectively]), and received IM atipamezole 60 minutes later. 
 
 
Figure 6. Mean ± SD of (a) dexmedetomidine and (b) levomedetomidine in sheep treated with IM 
medetomidine alone (MED [black circles]) or combined with vatinoxan (Med-Vat [white circles]), followed 
by IM atipamezole (MED+ATI and Med-Vat+ATI [black and white squares respectively]) or an equal volume 
of saline 30 minutes later (arrow). †Significant difference between MED and MMK, ‡Significant difference 
between MED+ATI and Med-Vat+ATI, §Significant difference between MED and MED+ATI, and 














































          
Figure 7. Mean ± SD of vatinoxan in sheep (a) treated with IM medetomidine (30 μg/kg) and ketamine (1 
mg/kg) combined with three different doses of vatinoxan (150, 300 & 600 μg/kg; Med-Ket-Vat150, Med-Ket-
Vat300 & Med-Ket-Vat600 [black squares, triangles & circles], respectively), and (b) treated with IM 
medetomidine (30 μg/kg) combined with vatinoxan 300 μg/kg (Med-Vat [white circles]), and followed by IM 
atipamezole 150 μg/kg (Med-Vat+ATI [white squares]) or saline 30 minutes later (arrow).  
    
Figure 8. Mean ± SE plasma concentration of (a) ketamine and (b) norketamine in sheep treated with IM 
medetomidine and ketamine (Med-Ket) with and without three different doses of vatinoxan (Med-Ket-Vat150, 
Med-Ket-Vat300 & Med-Ket-Vat600 [black squares, triangles & circles, respectively]), and received IM 
































Table 7. Median (range) of visual analogue sedation scores in nine sheep sedated with with IM 
medetomidine and ketamine (Med-Ket) alone and combined in the same syringe with three different 
doses of vatinoxan (Med-Ket-Vat150, Med-Ket-Vat300 & Med-Ket-Vat600), and received IM 
atipamezole 60 minutes later to reverse sedation (See Table 2 for treatments key and doses).  
 Time (min) 
Treatment Baseline 5 15 30 45 75 90 120 
Med-Ket 0 (0– 0) 3.3 (0.5–6) 8 (6–9) 9.5 (9–10) 9 (8–9) 0 (0–2) 0 (0–1) 0 (0– 4) 
Med-Ket-Vat150 0 (0–0) 4.3 (1– 5) 7 (4–9) 9 (7–10) 9 (7– 9) 0 (0–1) 0 (0–0) 0 (0–1) 
Med-Ket-Vat300 0 (0–0) 3.8 (3– 7) 8.5 (7–10) 9.5 (9–10) 9 (8–9) 0 (0–0) 0 (0–0) 0 (0–0) 
Med-Ket-Vat600 0 (0–0) 3.4 (1–6) 8.3 (5– 10) 9.7 (9– 10) 9 (8–9) 0 (0–0) 0 (0–0) 0 (0–0) 
 
 
Table 8. Median (range) of visual analogue sedation scores in eight sheep sedated with IM 
medetomidine (MED) alone and combined in the same syringe with vatinoxan (Med-Vat), and 
administered IM atipamezole (MED+ATI, Med-Vat+ATI) or equal volume of saline at 30 minutes to 
reverse sedation (See Table 2 for treatments key and doses). Significant difference from baseline is 
indicated by *; while † and ‡ denote significant differences between MED and Med-Vat, and 
MED+ATI and Med-Vat+ATI, respectively. 
 Time (min) 
Treatment Baseline 10 20 40 60 75 90 120 
MED 0 (0– 0) 4 (2–6)*† 7 (3–8)*† 6 (4–8)* 5.5 (4–7)* 5.5 (3–7)* 5.5 (3–6)* 3.5 (2– 4)*† 
MED+ATI 0 (0 –0) 4.5 (2– 7)*‡ 7 (4–9)*‡ 2.5 (0–7)* 0.5 (0– 7)*‡ 0.5 (0–5) 2.5 (0–5)* 1 (0–3) 
Med-Vat 0 (0–0) 5 (5– 8)* 8 (7–10)* 8 (6–10) 5 (4–7)* 5 (4– 7)* 3.5 (2–7)* 1.5 (0–3) 











































































































































































































































6.1 Cardiopulmonary effects    
In this series of studies, the effects of vatinoxan on cardiopulmonary function, plasma drug 
concentrations and clinical sedation were investigated in sheep treated with IM combinations of either 
medetomidine and ketamine or medetomidine alone (studies I–III). In general, following concomitant 
IM administration, vatinoxan dose-dependently alleviated most of the adverse cardiopulmonary 
effects associated with medetomidine and ketamine (study I). These results are consistent with the 
findings previously reported for sheep and dogs receiving vatinoxan combined with 
dexmedetomidine IV (Raekallio et al., 2010; Honkavaara et al., 2011), even though the study 
protocols were markedly different. However, in comparison with the IV studies, the early 
cardiopulmonary effects of medetomidine were not antagonized immediately (study I). Similar 
findings were reported for IM vatinoxan and medetomidine (Restitutti et al., 2017) and when the 
combination was further combined with butorphanol in dogs (Salla et al., 2014b). More specifically, 
in study I, HR and CO initially decreased significantly from baseline after all treatments, while MAP 
and CVP increased, except for the largest dose of vatinoxan (600 μg/kg). Likewise, PaO2 decreased 
significantly for up to 30 minutes, nonetheless with vatinoxan it remained significantly higher than 
without it (study I). These findings could be attributed to the slower absorption rate of vatinoxan 
when compared with that of medetomidine after IM administration. In dogs, vatinoxan reached its 
Tmax between 32–38 minutes, while the Tmax for dexmedetomidine varied between 9–17 minutes after 
concurrent IM injection (Restitutti et al., 2017). Consequently, we can deduce that in studies I and II, 
the early concentration ratio between vatinoxan and dexmedetomidine in plasma was probably less 
than would have been necessary to reverse the medetomidine-induced cardiopulmonary effects during 
the initial period following treatment administration. For instance, in dogs anesthetized with 
isoflurane, a 50:1 ratio of vatinoxan:dexmedetomidine in plasma significantly antagonized the 
medetomidine-induced effects on HR and MAP, although with higher ratios hypotension occured 
(Kaartinen et al., 2014). However, in sheep, no hypotension was observed even with the highest dose 
(600 μg/kg) as MAP remained above 60 mmHg at all times (studies I and II). It is likely that anesthesia 
with isoflurane might have impaired the cardiovascular function resulting in an increased sensitivity 
to vatinoxan’s vasodilatory action as reported by Kaartinen et al. (2014). In dogs and newborn lambs, 
isoflurane significantly decreased MAP in a dose-dependent manner (Brahim & Thut, 1984; Brett et 
al., 1987). In isoflurane-anesthetized dogs receiving vatinoxan (150 μg/kg IV) combined with 
medetomidine (10 μg/kg IV), MAP remained within clinically acceptable values (approximately 70 
mmHg) (Salla et al., 2017), whereas with higher doses of vatinoxan (250 μg/kg IV) hypotension was 
observed (Salla et al., 2014a). 
In study I, the addition of a small dose of ketamine to all treatments might have affected the 
pharmacodynamic interactions of vatinoxan and medetomidine. Ketamine is a cardiovascular 
stimulant, and when given IV (10 mg/kg) after xylazine (1 mg/kg, IV), it transiently, albeit 
significantly increased HR in xylazine-pretreated (1 mg/kg, IV) dogs. It also significantly increased 
CO, which nevertheless remained reduced when compared to values prior to xylazine administration 
(Haskins et al., 1986). Additionally, left ventricular work was increased, whereas SVR and left 
ventricle stroke index were significantly decreased after ketamine in xylazine-pretreated dogs, 





that received medetomidine (30 μg/kg) combined with ketamine (3 mg/kg) IM had a higher HR, 
compared with IM administration of medetomidine and butorphanol, even though all dogs were given 
glycopyrrolate as well (Ko et al., 2000). Similar findings were also reported for cats receiving 
ketamine and dexmedetomidine, 5 mg/kg and 10 μg/kg, IM, respectively, without any antimuscarinic 
treatment (Selmi et al., 2003). 
In studies I and II, DO2 decreased significantly from baseline after all treatments. Similarly, DO2 was 
significantly reduced in dogs receiving medetomidine alone (Enouri et al., 2008; Rolfe et al., 2012) 
or when combined with butorphanol (Salla et al., 2014b) after both IV and IM injections. In 
isoflurane-anesthetized cats, no significant changes from baselines within treatments were detected 
in DO2 after IM administration of dexmedetomidine (25 μg/kg) alone or when combined with 
vatinoxan (600 μg/kg), although a significant overall time effect was reported for both treatments 
(Siao et al., 2017). Oxygen delivery is a product of CO and arterial oxygen content (CaO2), where the 
latter is calculated from the arterial Hb concentration and PaO2. Consequently, any reduction in Hb 
content will negatively impact DO2. Therefore, in the aforementioned cat study, despite the 
significant decrease in CI after dexmedetomidine alone, DO2 remained statistically unchanged (Siao 
et al., 2017). The authors attributed this, among other probable reasons, to the increase in arterial Hb 
concentration after dexmedetomidine, which appeared to counteract the effect of the reduction in CI 
on DO2 (Siao et al., 2017). In studies I and II, the decreases in CO were small both in the presence 
and absence of vatinoxan. Therefore, the induced changes in DO2 can be attributed mainly to the 
reductions in Hb concentrations (and consequently, on CaO2) even though CO tended to be higher 
with vatinoxan than without it (studies I and II). In medetomidine-treated dogs (Enouri et al., 2008; 
Rolfe et al., 2012) both CI and DO2 decreased significantly either with or without vatinoxan, although 
CI was lower without the antagonist. However, with vatinoxan the oxygen extraction ratio (ER) 
remained within baseline values. The authors postulated, that due to the higher CI, addition of 
vatinoxan still maintained a better supply of oxygen to tissues as the increase in ER indicates a 
proportionate increase in demand versus supply (Rolfe et al., 2012). In studies I and II, however, the 
ER was not calculated due to lack of mixed-venous partial oxygen tension measurements. However, 
with all treatments, plasma lactate concentrations did not increase which would imply that tissues 
were adequately perfused and there was no tissue hypoxia. Lactate production, and thus its 
concentration in blood, increases as a result of a decreased cellular oxygen delivery. This relationship 
between increased lactate levels in blood and presence of an oxygen debt was first described by 
Meakins & Long (1927). Clinically, lactate levels in blood are frequently used to monitor tissue 
hypoxia.  
In study IV, when vatinoxan was given IV 10 minutes before dexmedetomidine, it prevented all the 
adverse pulmonary changes in sevoflurane-anesthetized sheep. As such, pulmonary edema can be 
defined as an accumulation of extravascular fluid in the lungs, most typically within the alveoli. 
Traditionally, two types of pulmonary edema are recognized, depending on the underlying cause: 
hemodynamic (cardiogenic) edema due to increased hydrostatic pressure, and permeability (non-
cardiogenic) edema due to increased endothelial permeability (Staub, 1974; Murray, 2011). 
Hydrostatic pulmonary edema associated with increases in MPAP, PAOP and pulmonary capillary 
pressure (PC) has been observed in sheep receiving dexmedetomidine (Kästner et al., 2007). On the 
other hand, the efflux of proteinaceous fluid into the alveolar spaces following ST-91, an α2-





et al., 1999b). In study IV, CT imaging suggested that the lung densities were increased following the 
administration of dexmedetomidine alone. This effect is comparable to the findings reported 
previously for sheep receiving 2 μg/kg IV dexmedetomidine (Kästner et al., 2007). However, the 
changes observed in study IV were less pronounced and developed more slowly than those reported 
by Kästner et al. (2007). Moreover, no abnormalities such as foamy fluid were evident during the 
bronchoscopy (study IV). Conversely, the post-mortem examination of sheep lungs with pulmonary 
edema revealed that the tracheas were filled with foamy fluid (Kästner et al., 2007). This 
inconsistency between the previous results and ours might be due to variation in individual sensitivity 
to α2-adrenoceptor agonists, even between individuals within the same breed. In addition, the use of 
PEEP during mechanical ventilation in study IV might have altered dexmedetomidine’s effects. In 
experimental canine and porcine models of induced pulmonary edema, the use of PEEP (10–20 
cmH2O) limited the increase in pulmonary extravascular fluid (Fernández-Mondéjar et al., 1996; 
Ruiz-Bailén et al., 1999), and significantly improved gas exchange and decreased the shunt fraction 
when compared to zero end-expiratory pressure (Wickerts et al., 1992). The application of PEEP 
effectively decreases the shunt fraction by recruitment of collapsed or unventilated sections of the 
lungs (Wickerts et al., 1992), increases total and/or regional functional residual capacity, and together 
with the subsequent prevention of the intermittent airway closure and opening, reduces the alveolar-
to-arterial pO2 gradient and venous admixture (McDonell & Kerr, 2015). Therefore, in study IV, 
although only 5 cmH2O of PEEP was used, it might have prevented detectable vascular changes and 
limited the formation of pulmonary edema. Further, since most of the CT changes were seen in the 
dependent, ventral part of the lungs, this could partially explain the lack of changes in BAL analyses 
as they were performed from the dorsal and accessory lung lobes. Additionally, the changes in CT 
could have been mainly due to the formation of interstitial rather than alveolar edema (study IV). It 
is also worth mentioning that the changes in PaO2 observed in studies I, II, and IV seemed to be 
reversible. In previous studies in sheep, later IV administration of α2-adrenoceptor antagonists (15–
20 minutes after the agonist), failed to completely reverse the hypoxemia induced by xylazine and 
medetomidine (Doherty et al., 1986; Ko & McGrath, 1995). Again, the variation in the extent of the 
induced morphological pulmonary changes might explain this discrepancy between the studies. 
Evident alveolar edema and hemorrhage were observed in sheep lungs 60 minutes after receiving 
xylazine (150 μg/kg, IV), and even 12 hours later a few areas of alveolar edema and hemorrhage 
persisted, suggesting a more pronounced pulmonary pathology when compared to the present studies 
I, II and IV (Celly et al., 1999a). In general, vatinoxan appeared to attenuate the cardiopulmonary 
changes induced by medetomidine after IM co-administration and also prevent dexmedetomidine-
induced pulmonary changes when administered as an IV pre-treatment. However, in conscious sheep, 
the improvement in cardiopulmonary function was somewhat lessened by a decrease in hemoglobin 
concentrations negatively impacting oxygen delivery. Moreover, presence of vatinoxan hastened 
complete reversals of medetomidine-induced cardiopulmonary changes by atipamezole as the two 
antagonists seemed to interacted favorably, without adverse effects in sheep sedated with 
medetomidine and/or medetomidine and ketamine.     
6.2 Plasma concentrations of drugs 
After concurrent IM administration in the same syringe, vatinoxan increased the early plasma 





reports in dogs (Restitutti et al., 2017) and cats (Pypendop et al., 2017b), as vatinoxan roughly 
doubled the Cmax of dexmedetomidine and reduced its Tmax in dogs (Restitutti et al., 2017) and cats 
(Pypendop et al., 2017b). This accelerated absorption of medetomidine probably resulted from 
reversal of the medetomidine-induced local vasoconstriction at the site of injection, as suggested by 
Restitutti et al. (2017). Moreover, vatinoxan approximately halved the Tmax for other sedative agents, 
butorphanol and midazolam, after single-syringe IM co-administration in dogs (Kallio-Kujala et al., 
2018a). Interestingly, the aforementioned effect of vatinoxan on medetomidine concentrations was 
not detected after co-administration with ketamine (study I). This could possibly be attributed to a 
direct vasodilatory effects on the peripheral vasculature by ketamine, mimicking the local effects of 
vatinoxan (White et al., 1982). Further, the acidity of the ketamine solution (pH 3.5–5.5) might have 
changed the mixture’s pH. Medetomidine pKa is 7.1 which means that at pH 7.1 its base and salt 
forms will be present in a 50:50 ratio. Thus, the percentage of non-ionized medetomidine could be 
increased at acidic pH and subsequently increases its absorption rate. Also, addition of the ketamine 
preparation may have changed the solution’s physicochemical properties that could have led to the 
increase of medetomidine absorption. No reports are available concerning effects of ketamine on the 
absorption of α2-adrenoceptor agonists or other drugs after IM administration. In cattle, sheep 
(Deghani et al., 1991), and blue foxes (Jalanka, 1990) the onset of sedation following IM 
administration of xylazine or medetomidine combined with ketamine was faster when compared with 
the α2-adrenoceptor agonist alone, although this may have been due to additional central depressive 
effects by the dissociative. In studies II and III, blood samples for drug concentration analyses were 
not collected frequently enough to precisely determine the absorption phase so comparing absorption 
kinetics between studies I, II and III is not possible. However, the plasma concentrations of dex-, 
levomedetomidine, and vatinoxan seemed higher in study I than when measured in studies II and III. 
For instance, with Med-Ket treatment in study I the plasma concentrations of dexmedetomidine at 
T20 and T30 were significantly higher than those in studies II and III after medetomidine alone. A 
comparable effect of ketamine on vatinoxan was observed as the plasma concentrations of vatinoxan 
with the middle dose in study I (Med-Ket-Vat300) at T20 and T30 seemed to be higher than with 
Med-Vat and MED+VAT in studies II and III respectively. However, the difference was not 
statistically significant. Additionally, in study II, the semimembranosus muscle was used for 
treatment administration, whereas the shoulder muscles were the assigned muscle group in studies I 
and III. The activity and blood flow of the muscle affect drug bioavailability (Buxton, 2006). The 
postural muscles usually have more abundant blood flow that hastens drug absorption compared with 
nonpostural muscles (Baxter & Evans, 1973). Moreover, the amount of peri-muscular fat or 
intermuscular fascial planes can decrease the rate of drug absorption (Sund & Schou, 1964). In dogs, 
for instance, the onset of sedation was faster, and its quality was higher after IM dexmedetomidine 
and hydromorphone administered into the semimembranosus and cervical muscles compared with 
lumbar and gluteal ones (Carter et al., 2013). Furthermore, in dairy cows, amoxicillin absorption from 
M. triceps was better than from the buttocks (Rutgers et al., 1980). No such data comparing the effect 
of IM injection sites on the absorption of sedative drugs in sheep are available.  
On the other hand, vatinoxan significantly increased the CL of (dex-)medetomidine following 
simultaneous IV administration in dogs (Honkavaara et al., 2012; Bennett et al., 2016). Similarly, in 
cats, dexmedetomidine CL was significantly higher with vatinoxan after both IV (Pypendop et al., 





study II, though our follow-up period was relatively short compared with some of the previously 
mentioned studies, vatinoxan seemed to enhance the CL of medetomidine. The plasma concentrations 
of dex- and levomedetomidine were significantly lower in the presence of vatinoxan from 60 and 90 
minutes onwards in studies II and III, respectively. Arguably, increased biotransformation related to 
enhancement of hepatic blood flow by vatinoxan could partly explain these differences although it 
was not directly evaluated during our studies.  
In studies I–III, plasma concentrations of dex- and levomedetomidine appeared nearly identical, 
regardless of the presence or absence of vatinoxan, ketamine or atipamezole. Conversely, in dogs, 
dexmedetomidine concentrations were significantly higher than those of levomedetomidine after both 
IV (Bennett et al., 2016, 2017) and IM (Kallio-Kujala et al., 2018a) administration of the racemic 
mixture, which should theoretically contain equal amounts of both enantiomers. However, when the 
pharmacokinetics of medetomidine (40 μg/kg) and its enantiomers, dexmedetomidine (20 and 10 
μg/kg) and levomedetomidine (20 and 10 μg/kg), were compared after IV administration in dogs 
(Kuusela et al., 2000), no significant differences in CL, VSS, or T½ were detected between 
medetomidine and dexmedetomidine. That said, the CL and VSS of levomedetomidine were 
significantly higher and larger than with dexmedetomidine and the racemic medetomidine, while the 
T½ did not significantly differ between the enantiomers (Kuusela et al., 2000). Nevertheless, in the 
aforementioned study, all the drugs were administered separately, which means that 
levomedetomidine’s pharmacokinetics were determined without the cardiovascular depressant effect 
of dexmedetomidine (Kuusela et al., 2000). However, in dogs treated with racemic medetomidine (10 
μg/kg IV), the T½ of dexmedetomidine was significantly lower than that of levomedetomidine, 
whereas the AUC and concentrations of dexmedetomidine in plasma were significantly higher than 
for the levoisomer (Bennett et al., 2016). Further, in dogs, after administration of medetomidine, the 
clearance of levomedetomidine was significantly higher than that of dexmedetomidine, both in the 
presence and absence of vatinoxan (Bennett et al., 2016; Kaartinen, 2016). Consequently, as no such 
differences were noted, we can deduce that in sheep the clearance of the enantiomers seems to differ 
less than in dogs.             
Administration of atipamezole resulted in marked increase in both dex- and levomedetomidine 
concentrations in plasma (studies II and III). For instance, with medetomidine alone, concentrations 
of dex- and levomedetomidine were approximately tripled 10 minutes after atipamezole (study II). 
However, in the presence of vatinoxan, pre-reversal concentrations were not exceeded (study II). This 
difference could be attributed to the earlier achievement of Cmax in the presence vatinoxan, as 
mentioned. Nevertheless, the increase in medetomidine concentration after atipamezole 
administration is a well-documented phenomenon in ruminants (Ranheim et al., 1997; 1998; 1999; 
2000b). For example, in sheep receiving IV atipamezole (200 μg/kg) 60 minutes after IV 
medetomidine (40 μg/kg), the maximum increase (approximately two- to three-fold) in medetomidine 
concentrations in plasma was detected 5 minutes after atipamezole administration and they remained 
elevated between 25 to 45 minutes before regaining pre-reversal concentrations (Ranheim et al., 
2000b). This phenomenon has not been observed in other species, such as dogs (Salonen et al., 1995), 
horses (Knych et al., 2012), ponies (Dyer et al., 1987) or humans (Scheinin et al., 1998). Presumably, 
atipamezole might have displaced medetomidine from highly perfused organs such as kidneys, CNS, 
lungs and liver thus increasing its concentration in plasma, as previously suggested by Ranheim et al. 





from its injection site, due to improvement of global cardiovascular function (study II). In contrast, 
after medetomidine alone its concentrations in plasma were stable throughout the follow-up period, 
suggesting equal absorption and elimination rates, or a flip-flop phenomenon (study II). Further, in 
sheep receiving IM medetomidine (30 μg/kg), the Tmax ranged between 15-40 minutes and Cmax was 
4.98 ± 1.9 ng/mL (Kästner et al., 2003), which possibly reflected a slower absorption rate from the 
assigned muscle group in study II compared to ones used by Kästner et al. (2003). On the other hand, 
in study I, the Tmax was shorter than reported earlier (32.5–38.1 minutes) for dogs receiving various 
doses of IM vatinoxan in combination with medetomidine (Restitutti et al., 2017). Administration of 
atipamezole had no significant effect on vatinoxan concentrations in plasma (studies I–III), nor were 
the concentrations of atipamezole affected by the presence of vatinoxan (studies I–III). On the 
contrary, in dogs, vatinoxan significantly decreased plasma concentration of atipamezole and reduced 
its AUC in dogs receiving medetomidine (Turunen et al., 2017).  
6.3 Clinical sedation 
The AUCs of sedation scores from study I showed no significant differences in the level of sedation 
between treatments regardless of the addition of vatinoxan, which was probably attributed to 
ketamine as discussed earlier. However, the lowest dose of vatinoxan (150 μg/kg) did not completely 
reverse the adverse cardiopulmonary effects of Med-Ket. The highest dose (600 μg/kg), on the other 
hand, provided no additional benefits and two animals passed abnormally soft feces. Thus, the middle 
dose of vatinoxan (300 μg/kg) appeared to be the optimal one for concurrent IM administration with 
300 μg/kg medetomidine. Addition of that dose of vatinoxan to medetomidine produced a more rapid 
onset of sedation in sheep than with medetomidine alone (studies II and III). This finding is consistent 
with previous studies in dogs (Restitutti et al., 2017; Kallio-Kujala et al., 2018a, b) and cats 
(Honkavaara et al., 2017b). In dogs, the time to peak sedation was in line with the Tmax of 
dexmedetomidine (Kallio-Kujala et al., 2018a). These increased sedation scores could be due to the 
accelerated absorption of medetomidine from the injection site by the addition of vatinoxan, resulting 
in an earlier and higher Cmax for medetomidine. Restitutti et al. (2017) suggested that vatinoxan might 
have reversed the local vasoconstriction induced by medetomidine. On the other hand, from 90 
minutes onwards, the level of sedation was higher after medetomidine alone than when vatinoxan 
was added (study II). These findings seemed to directly reflect the plasma concentrations of 
dexmedetomidine. Dexmedetomidine is also known to have a ceiling effect above which increasing 
the dose (or actually concentration in plasma) does not further deepen the sedation. For example, in 
domestic cats receiving a stepwise infusion of medetomidine, the depth of sedation was dose-
dependent up to certain serum concentration (45 ng/mL, dexmedetomidine) and beyond that level the 
sedation degree was decreased (Ansah et al., 2000). Further, in sheep, the observed degree of sedation 
correlated well with the concentration in plasma after IM medetomidine (30 μg/kg) at the peak plasma 
concentration and a Tmax of (range) 15–40 minutes (Kästner et al., 2003). Similarly, after IV 
medetomidine (15 μg/kg and 40 μg/kg) the sedative effects declined in parallel with plasma 
medetomidine concentrations (Muge et al., 1996; Ranheim et al., 2000b). In contrast, in some other 
ruminants such as cattle and reindeer, medetomidine concentrations appeared to correlate less directly 
with its sedative effects (Ranheim et al., 1997, 1998, 1999). Overall, it seemed that the degree of 





example, one animal showed a low sedation scores after Med-Ket treatment, which was associated 
with low dexmedetomidine plasma concentrations.  
Reversals with atipamezole were smooth and uneventful both with or without vatinoxan (studies II 
and III). In contrast, in study I, most of the animals showed signs of agitation, excitement and facial 
muscle tremors after atipamezole administration. The timing of atipamezole administration (30 
minutes after medetomidine in studies II and III versus 60 minutes after medetomidine-ketamine in 
study I) might explain these differences, because the longer interval unsurprisingly lead to lower 
plasma dexmedetomidine concentrations at the time of reversal, favoring the clinical effects of 
atipamezole. In a previous study in sheep (Ranheim et al., 2000b), all the animals exhibited similar 
over-alertness and muscle tremors when atipamezole (200 μg/kg IV) was administered 60 minutes 
after medetomidine (40 μg/kg IV). On the other hand, sheep appeared alert when sedation was 
reversed by atipamezole (200 μg/kg IV) immediately after the animals had become recumbent 9–25 
minutes after 40 μg/kg IM medetomidine was given (Mohammad et al., 1995). Thus, we can conclude 
that when the sedative effects of medetomidine have already been considerably dissipated, a lower 
dose of atipamezole might be preferable. This conclusion is supported by earlier results of Talke et 
al. (2000), who reported that administration of atipamezole at a dose 2.5 times that of a preceding 
medetomidine dose in sheep, no excitement or agitation was observed. Moreover, when IV 
atipamezole (30 or 60 μg/kg) was given to lambs 15 minutes after medetomidine (30 μg/kg IM), all 
the animals recovered and walked unassisted in 2.4 ± 0.4 and 2.3 ± 0.7 minutes respectively (Ko & 
McGrath, 1995). Additionally, the possible residual effects of ketamine at the time of atipamezole 
administration may have contributed to the observed agitations and tremors in study I.  
Following the initial recovery after atipamezole, some of the animals treated with medetomidine 
alone (studies II and III) or medetomidine-ketamine (study I) became lethargic and seemed drowsy. 
With the addition of vatinoxan, fewer animals seemed to exhibit these signs. Honkavaara et al. (2008) 
postulated that the presence of vatinoxan might have enhanced the central bioavailability of 
atipamezole by decreasing the amount of atipamezole bound to peripheral α2-adrenoceptors, thus 
leading to more complete reversals. However, in an earlier study, no relapse into sedation was 
observed after the reversal of medetomidine-induced sedation by atipamezole in sheep (Ranheim et 
al., 2000b). In contrast, in dairy calves and cattle, resedation was evident approximately 80 minutes 
after atipamezole administration (Ranheim et al., 1998; 1999), and between 30–60 minutes after 
atipamezole injection to reindeer (Ranheim et al., 1997). In free-ranging cattle sedated with 
medetomidine, resedation was detected between 1–2 hours and 3–4 hours after IV and IM 
atipamezole, respectively (Arnemo & Soli, 1993b; 1995). In studies I and II, the assessment of 
resedation was compromised by the use of a sling, the concurrent physiologic measurements, and the 
relatively short observational period after reversal (60 minutes in study I and 90 minutes in study II). 
Therefore, in study III, all sedation assessments were performed from a distance, without approaching 
or interacting with the animals. However, when the animals became sternally recumbent, it became 
challenging to recognize resedation. Overall, vatinoxan appeared to ensure more complete recoveries 
when atipamezole was used to reverse medetomidine-elicited sedation. The rapid onset of sedation 
and lack of resedation after reversal are advantageous, especially with free-ranging and non-





6.4 Other effects 
6.4.1 Rectal temperature 
In study I, rectal temperature decreased significantly after all treatments. Even after reversal with 
atipamezole, it remained below the baseline, although remaining within an acceptable physiological 
range (38.3–39.9°C). Similar results were reported in calves after sedation with medetomidine and 
ketamine (Raekallio et al., 1991) and medetomidine alone followed by atipamezole (Rioja et al., 
2008). Decreases in temperature after the use of α2-adrenoceptor agonists are a well-documented 
phenomenon (Ponder & Clark, 1980; Virtanen, 1989; Keegan et al., 1995; Pypendop et al., 1996; 
Honkavaara et al., 2017b). On the other hand, a rise (Ranheim et al., 1999; Rioja et al., 2008) or no 
change (Mohammad et al., 1993; 1995) in core temperature have also been reported. The reduction 
in temperature after α2-adrenoceptor agonists is attributed to CNS depression and decreases in 
muscular activity (Sinclair, 2003). Moreover, a proposed biphasic effect of medetomidine on rectal 
temperature has been suggested, characterized by a brief, initial rise as a result of peripheral 
vasoconstriction followed by a prolonged decrease due to the reduced muscular activity (Kuo & 
Keegan, 2004). This proposed biphasic effect is supported by the finding in dogs of Rolfe et al. 
(2012), where the concurrent administration of vatinoxan with medetomidine prevented the initial 
increase in rectal temperature but not the subsequent decrease, presumably by preventing the 
peripheral vasoconstriction. In dogs sedated with medetomidine and butorphanol, the addition of 
vatinoxan resulted in a significant increase in superficial temperatures measured by thermography, 
accompanied by a significant decrease in rectal temperature (Vainiopää et al., 2013a). This suggested 
that the enhancement of peripheral blood flow by vatinoxan led to an increase in peripheral heat loss 
(Vainiopää et al., 2013a). Jalanka & Roeken (1990) suggested that hypo- or hyperthermia could 
develop if immobilized animals are exposed to extreme ambient temperature for long periods. For 
instance, at room temperature, rectal temperatures remained stable in snow leopards (Jalanka, 1989) 
and blue foxes (Jalanka, 1990) receiving medetomidine, but in markhors immobilized with 
medetomidine-ketamine at ambient temperatures between 5 and 12°C, they were significantly 
decreased (Jalanka, 1988). In cats, xylazine-induced hypothermia developed more rapidly when 
animals were placed in a cold environment (4°C), whereas at hot ambient temperature (32°C) a mild 
hyperthermia developed instead (Ponder & Clark, 1980). Therefore, it could be concluded that α2-
adrenoceptor agonists seem to affect thermoregulation rather than the body temperature itself. 
Consequently, the aforementioned variation more likely depends on the ambient temperature. In our 
studies, no increase in rectal temperatures were recorded regardless of the presence or absence of 
vatinoxan. However, we might have missed the initial changes in body temperature because the first 
measurements were made 15 and 10 minutes after the treatments were administered in studies I and 
II, respectively. Further, the studies were carried out at an ambient room temperature of 20–22°C, 
with no other further efforts aimed at maintaining normothermia. However, vatinoxan may pre-
dispose animals to more pronounced changes in core temperature as they may become more 
vulnerable to the surrounding conditions. 
6.4.2 Hemoglobin content 
Blood hemoglobin concentrations were significantly decreased from baseline with all treatments 
(studies I and II). However, with the treatments without vatinoxan, Hb concentration remained higher 





lower in dogs treated with medetomidine and vatinoxan than that after medetomidine alone. Thus, 
vatinoxan might have antagonized the peripheral effect of medetomidine on the splenic capsule, as 
(dex-)medetomidine alone has been reported to increase Hb concentration in dogs (Rolfe et al., 2012) 
and cats (Siao et al., 2017). In horses, on the other hand, α2-adrenoceptor agonists caused a marked 
decrease in packed cell volume (Gasthuys et al., 1990; Wagner et al., 1991; Kullmann et al., 2014) 
and Hb concentrations (El-Kammar & Gad, 2014), associated with increases in splenic thickness 
(Kullmann et al., 2014). Any decrease in sympathetic tone can lead to splenic relaxation and 
consequently red blood cell sequestration in horses (Wagner et al., 1991; Kullmann et al., 2014). The 
lack of change in study IV after either treatment could be attributed to the relatively small agonist 
dose used. By itself, sevoflurane unlikely affected the Hb concentration because no changes were 
detected in Hb levels in humans that inhaled 1 MAC sevoflurane (Bozdogan et al., 2005). In any case, 
the more pronounced decrease in Hb concentrations associated with vatinoxan decreased CaO2, as 
discussed earlier. Reversal with atipamezole returned Hb concentrations to baseline levels with all 
treatments (studies I and II). 
6.4.3 Plasma glucose concentration 
The hyperglycemic effect of medetomidine observed in studies I, II, and IV was expected as it is a 
well-documented phenomenon in several species following the use of various α2-adrenoceptor 
agonists (Hsu & Hummel et al., 1981; Burton et al., 1997; Ranheim et al., 2000a; Carroll et al., 2005). 
Vatinoxan prevented the increase in plasma glucose and maintained its concentrations close to 
baseline levels (studies I, II, and IV). Similar findings were reported for dogs receiving IV 
dexmedetomidine combined with vatinoxan, where the antagonist prevented the dexmedetomidine-
induced decrease in plasma insulin concentrations and the consequent hyperglycemia (Restitutti et 
al., 2012). Also, in horses, vatinoxan partially prevented romifidine-evoked hyperglycemia 
(Pakkanen et al., 2018). In studies I and II, administration of atipamezole did not reverse the effects 
of medetomidine on plasma glucose. This is consistent with an earlier finding in sheep where 
atipamezole did not reverse the primary hyperglycemia but prevented the secondary further increase 
in glucose concentration (Ranheim et al., 2000a). In contrast, in dairy cows and calves, atipamezole 
clearly antagonized medetomidine-induced hyperglycemia (Ranheim et al., 2000a).  
6.5 Methodological considerations and study limitations 
We used only intact female sheep in this series of investigations. However, sex predilection is an 
unlikely cause of differences in the hypoxemic response to α2-adrenoceptor agonists in this species 
(Nolan et al., 1990; Celly et al., 1997a). However, the individual variability in response to α2-
adrenoceptor agonists is common among sheep. Breed differences was suggested as a cause of 
dissimilarity in sheep analgesic response to IV xylazine (Ley et al., 1990). On the other hand, 
extensive individual variation in the hypoxemic response to medetomidine has been reported (Tulamo 
et al., 1995). Moreover, Kästner et al. (2007) reported that out of seven sheep that received IV 
dexmedetomidine, one showed only minimal systemic and pulmonary vasoconstriction during the 
study, which was later confirmed by the lack of pulmonary capillary disruption in the post mortem 
examination. In contrast, the same group (Kästner et al., 2003) reported that one individual sheep out 
of nine became hypoxemic with PaO2 decreased below 60 mmHg after IM medetomidine (30 μg/kg), 





accordance, we noticed substantial individual variability in PaO2, although severe hypoxemia was 
only sporadically noted. Among the animals used in the present studies, there were some individuals 
whom exhibited low PaO2 across the treatments while others did not. In study IV, for instance, in two 
sheep, PaO2 was more than halved from baseline after dexmedetomidine alone, although 
administration of vatinoxan before dexmedetomidine prevented the decrease in PaO2 in all 
individuals.  
Two distinct Hb types (Hb A and Hb B) are commonly found in adult sheep (Evans et al., 1956; 
1958). Accordingly, three types of animal can be distinguished based on their Hb type, i.e. A, B, or 
AB. The PaO2 at which Hb is half saturated (P50) varies among sheep depending on their Hb type. 
Maginniss et al. (1986) reported that P50 was 31 mmHg for sheep with Hb A, while it was 40 and 35 
mmHg for Hb B and Hb AB sheep respectively. However, in the present study no Hb characterization 
was performed. Thus, in studies I and II, the standard formula for Hb AB was used for calculation of 
saturation indices, whereas in study IV, no saturation calculations were performed and SpO2 was 
recorded with pulse oximetry. Moreover, the accuracy of Hb concentrations in studies II and IV might 
be questioned because they were obtained from blood gas analyses performed by analyzers using 
algorithms designed for humans. However, the studies aimed to compare effects between treatments 
and all samples were analyzed similarly. Additionally, a similar treatment effect was observed on Hb 
in study I when the samples were analyzed using a hematology analyzer validated for sheep. 
Furthermore, the repeated blood sampling for LiDCO, plasma drug concentrations, and blood gas 
analyses, might have affected the Hb concentration, blood volume and subsequently the 
cardiopulmonary parameters. However, the maximum blood loss during the studies was much less 
than 10% of the estimated total blood volume, with 14 days of rest between each two consecutive 
trials (Morton et al., 1993; Diehl et al., 2001). Therefore, the blood loss and IV fluid replacement 
were unlikely to markedly affect the results as compared to the effect of treatments.      
In studies I, II and IV, CO was measured using the lithium dilution method. In anesthetized sheep, 
lithium dilution was suggested to be biased when tested against a pulmonary arterial flow detector 
probe as it did not detect changes in CO reliably enough. However, the results were comparable to 
those reported for other animal studies (Axiak Flammer et al., 2013). Nevertheless, in anesthetized 
pigs, lithium dilution performed better than thermodilution when the accuracy of both methods were 
compared against a flow detector probe (Kurita et al., 1997). In dogs, LiDCO and thermodilution 
measurements correlated well (Mason et al., 2001). Also, in dogs with experimentally induced, 
normo-, hypo-, and hyperdynamic hemodynamic conditions, there was a good agreement between 
LiDCO and thermodilution (Morgaz et al., 2014). In vitro, medetomidine and ketamine can react with 
the lithium sensor and increase its voltage, which can affect the reported values (Ambrisko et al., 
2013). However, the magnitude of this effect is concentration dependent. In our studies, 
concentrations of medetomidine and ketamine in plasma were much lower than those that reportedly 
cause any appreciable bias: only the ketamine concentration in study I was > 300 ng/mL, which can 
induce a bias of 1.9% (Ambrisko et al., 2013). Moreover, in vivo biases with clinically relevant plasma 
concentrations have been reported for some drugs, such as xylazine in horses (Ambrisko & Moens, 
2014), but atipamezole does not markedly interfere with the performance of the lithium sensor 
(Ambrisko et al., 2013). However, no data are available on the interaction between vatinoxan and the 
lithium sensor, thus we are not able to determine whether this may have influenced the accuracy of 





other than sheep, therefore it is difficult to estimate the potential influence of the drugs used on the 
lithium sensors. It seems unlikely that these interactions would have had a significant impact 
compared with the effect of vatinoxan on CO, which is well documented in other species and using 
other methods (Enouri et al., 2008; Rolfe et al., 2012; Siao et al., 2017; Martin-Flores et al., 2018). 
However, a further investigation would be warranted to determine the potential effects of vatinoxan 
on lithium sensor voltage which may bias the CO measurements. Additionally, any cumulative 
increase in blood lithium concentration might affect the accuracy of CO measurements. The 
manufacturer determined a serum lithium concentration of 0.2 mmol/L as a cutoff value, above which 
an overestimation of CO due to background lithium is expected. However, in the present study, 
residual background lithium was an unlikely cause for any bias since no more than seven lithium 
injections of 0.075 mmoL each were given during a trial. In dogs, for example, 34 lithium doses 
within the span of 3–7 hours are needed to reach 0.2 mmol/L limit (Mason et al., 2002).   
In studies I and II, the sheep were placed in a sling that kept them in an upright position with limited 
ability to move, which may have impaired the assessment of sedation and its reversal. Additionally, 
the heavy instrumentation and the simultaneous cardiopulmonary measurements might have affected 
the overall degree of sedation. Therefore, study III focused primarily on sedation evaluation with the 
animals unrestrained and allowed to behave normally without interference.  
In studies I, II, and IV, the blood samples for plasma drug concentrations were collected from the 
carotid artery, whereas in study III (due to lack of arterial cannulation) the samples were obtained 
from the jugular vein. The drug concentrations in venous blood samples may vary depending on the 
vein being sampled (Chiou, 1989) and sometimes they are proportional to the drug concentration in 
the tissues drained by that vein (Lam et al., 1982). Arterial blood samples, on the other hand, are 
independent of sampling site and generally preferred when studying the relationship between plasma 
concentrations and effect (Chiou, 1989). In cats, for instance, jugular venous blood sampling resulted 
in an overestimation of plasma buprenorphine concentrations after buccal administration compared 
to carotid arterial blood sampling; however, no difference between the two sites was observed in 
calculated pharmacokinetic parameters following IV administration (Hedges et al., 2014). In the 
present study, it was unlikely that the sampling site markedly affected the plasma drug concentrations 
since the plasma concentrations in studies II and III were comparable. Further, the samples in study 
III were collected from the upper third of the jugular vein, while the shoulder muscles venous drainage 
ends up in the axillary vein which drains into the subclavian vein to cranial Vena cava (Schummer et 
al., 1981).                
6.6 Clinical relevance and future prospects 
When administered intramuscularly in the same syringe, vatinoxan dose-dependently alleviated the 
cardiopulmonary effects of medetomidine without compromising sedation. In fact, vatinoxan 
appeared to shorten the onset of sedation and was also associated with more complete recoveries after 
reversal with atipamezole. These findings might prove very useful, especially in field conditions. 
Apart from sheep, vatinoxan could enhance the safety of medetomidine and medetomidine-ketamine 
sedation in various non-domestic ruminant species, although re-evaluation of the optimal doses would 
be necessary. In sheep, as the current studies were experimental and performed under well-controlled 





further elucidation of the pharmacokinetic-pharmacodynamic interactions between vatinoxan, 
medetomidine, atipamezole and other sedatives, anesthetics and analgesics are required to describe 
clinically relevant outcomes such as anesthetic-sparing, antinociception and gastrointestinal function 
both in sheep and other ruminant species.  
The present studies revealed that vatinoxan dose-dependently counteracted the hyperglycemic effect 
of (dex-)medetomidine. Nevertheless, the study design investigated only clinically healthy 
individuals and metabolic outcomes were not prioritized. Therefore, a further elucidation of 
vatinoxan’s effects on metabolic changes prompted by α2-adrenoceptor agonists in sheep requires 
future research, especially in compromised or stressed animals and those with underlying diseases. 
Additionally, study designs including a vatinoxan only treatment arm would have added more 







1. Vatinoxan dose-dependently attenuated most of the cardiopulmonary suppression in conscious 
sheep sedated with medetomidine and ketamine. The presence of vatinoxan hastened the reversal by 
atipamezole.   
2. Vatinoxan increased the early concentrations of medetomidine in plasma when co-administered 
IM in the same syringe.  
3. Vatinoxan had no significant effect on ketamine concentrations, when both were administered in 
combination with medetomidine, or on atipamezole concentrations administered later for sedation 
reversal. 
4. Vatinoxan increased the intensity of clinical sedation induced by medetomidine following 
concurrent IM administration, whereas it had no clinically relevant effect on the sedation scores 
produced by a medetomidine and ketamine combination. Vatinoxan ensured more complete 
recoveries when atipamezole was used to reverse medetomidine or medetomidine and ketamine-
induced sedation. 
5. Pre-treatment with vatinoxan prevented dexmedetomidine-induced pulmonary alterations such as 
pulmonary edema formation and increase in airway resistance while reducing the decreases in PaO2 
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